Stock offerings, IPOs, PIPEs, convertible notes, buybacks and other money raises by public biotech companies, newest first. Every story links its primary source.
Financings ·
The offering priced at $1.50 a share, and the warrants carry a $1.65 exercise price. The auditor's report on the 2025 accounts includes a going-concern paragraph, and cash was $18.4 million at June 30, 2026.
INMBA city skyline in morning haze. CC0, via rawpixel
Financings
Lexeo's new Form S-3 would let it sell up to $300,000,000 of securities and rolls over $135,387,220.20 of unsold securities from a December 2024 shelf. No offering has been priced.
LXEO
Financings
ProKidney can sell up to $200,000,000 of Class A stock through Jefferies LLC at a commission of up to 3.0%, under a $650,000,000 shelf that the filings say must take effect before any sale. The stock last sold at $1.52 on October 28, 2026.
PROK
Financings
Actuate Therapeutics priced 30,985,900 shares and warrants for 15,492,950 more shares at $0.71 per set, for about $11.0 million before costs. The stock last sold at $0.40, and the company reported $4.4 million of cash at June 30, 2026.
ACTU
Financings
Adial Pharmaceuticals becomes Azora Therapeutics and is expected to trade as AZR from October 29, 2026, after stockholders approved converting the preferred stock issued in its June 2026 acquisition of Azora. The October release does not mention AD04, the drug the company's March 2026 annual report called its lead asset.
ADILSilexion's S-3 registers resale of up to 8,813,531 ordinary shares by selling shareholders from an August warrant inducement, a converted sponsor note and stock paid to LifeSci Advisors. The filing also discloses a June 2026 complaint from the sponsor, which seeks repayment of $3.433 million.
SLXNAclaris priced 7,785,714 shares at $3.50 and pre-funded warrants for 6,500,000 more shares, $49,999,934 before costs, on the day it announced small Phase 1b results for its antibody ATI-052. The prospectus puts cash at approximately $204.6 million on September 30, 2026.
ACRSAn addendum with C/M Capital Master Fund lifts the facility's maximum commitment from $35 million to $135 million. The filing does not say how much stock has been sold under it.
EDVAImunon's preliminary prospectus covers up to 20,000,000 shares, sold with warrants that could cover up to 70,000,000 more. The auditor's opinion on 2025 results includes substantial doubt about the company's ability to continue as a going concern.
IMNNRapport Therapeutics filed preliminary terms on October 27, 2026 for a stock offering and convertible notes due 2032. Both deal sizes are blank in the filings, and the company's cash was about $395.0 million at September 30, a figure it calls preliminary.
RAPPValion Bio sold 4,717.73 Series C preferred shares for $4,717,717.61, but $3,217,717.61 of that stays with the buyers to cover overdue cash true-up payments. The company receives $1,500,000 in cash.
VBIOThe S-3 covers common stock, preferred stock, debt securities and warrants, with pricing and terms to come in later prospectus supplements. Acumen's auditor included a going concern paragraph in its report on the 2025 financial statements.
ABOSEquillium says the first subject has been dosed in a Phase 1 trial of EQ504, which releases a $20 million tranche of its 2025 private placement. The company says that with this closing its cash should fund planned operations into 2029.
EQTraws can sell up to $50,000,000 of new stock to Roth over 36 months, but no shares can be sold until the SEC declares a resale registration effective. Cash was $5.0 million on June 30, 2026, and cash used in operations was $18.2 million in 2025.
TRAWThe new program runs through Oct. 21, 2027, on top of a September accelerated repurchase that is still open. The company's cash was $3.80 billion at June 30.
UTHRSagimet's investor presentation says $257.6 million in cash, cash equivalents and marketable securities at June 30, 2026, plus a $115 million underwritten offering completed in September, should fund operations to mid-2029. The presentation does not name the underwriters.
SGMTThe offering priced below the $19.10 last reported sale price. Arcus says the money goes mainly to casdatifan, its HIF-2 alpha inhibitor now in two phase 3 programs.
RCUSChina SXT and the purchasers in its October 8, 2026 registered direct offering agreed to cancel, in full, a right to buy up to $12 million more shares. The company says the offering's securities already issued are not affected.
SXTCThe upsized offering funds a planned bitopertin launch. Disc says cash plus proceeds lasts into 2030 and had an estimated $682.8 million before the deal.
IRONSurrozen sold 5,741,605 shares, pre-funded warrants and Series E warrants after FDA cleared its SZN-8141 IND application. It expects its cash, cash equivalents and marketable securities to last into 2029.
SRZNBioAtla can sell up to $40.0 million of stock to Yorkville over 36 months, but its cash was $1.5 million at June 30, 2026, and its prior $15.0 million line raised about $0.4 million.
BCABIndaptus sold 20,338,974 shares for approximately $24.0 million after the closing date was pushed back. Its cash was $7.6 million at June 30, 2026, and its 2025 net loss was $20.8 million.
INDPThe second tranche brought in about $95.1 million gross, before placement agent fees, and the company expects cash to last into 2029. The first patient in its SZN-8141 trial is not expected to be dosed until the fourth quarter of 2026, after a rival Wnt drug met its primary endpoint in a Phase 2b/3 trial in the same eye disease.
SRZNThe offering totals $40,000,000 at the public offering price, with $37,600,000 to Teknova before expenses. Underwriters have a 30-day option to buy up to 1,200,000 more shares.
TKNOCuris sold shares and pre-funded warrants at an effective $0.51 a share, with common warrants at $0.60. A.G.P./Alliance Global Partners, the lead placement agent, earns a 6.5% cash fee on the gross proceeds.
CRISDogwood will issue 4,098,360 shares at $1.22 each, with no warrants, in a deal expected to close by October 29, 2026. The company says the proceeds extend its runway through March 2027, after cash of $9.6 million at June 30, 2026.
DWTXOS Therapies raised $7.2 million gross in the first closing of a warrant inducement, but the holders who exercised received new warrants for the same number of shares at $1.40, and the company reported only $205,035 in cash at June 30, 2026.
OSTXThe Cambridge RNAi developer sold 11.1 million shares at the midpoint of its range. Its lead drug, a Factor XI siRNA for blood clots, has more phase 1 data due in late 2026.
CTYSLNThe investor waived limits that would have blocked a larger at-the-market offering, in exchange for a new warrant at $5.02 per share. WallachBeth Capital LLC also waived its rights under the sales agreement.
TNONAlector priced 36,600,000 shares at $2.05 for $75,030,000 gross. Its 2025 revenue fell to $21.0 million and cash used in operations was $184.0 million, against $59.9 million of cash on June 30, 2026.
ALECThe exchange leaves Maze with 53,931,889 shares of common stock outstanding as of October 16, 2026.
MAZEThe company says cash now lasts into 2029. Sanofi's option on an inflammatory disease molecule triggered a $10 million milestone.
RXRXALX Oncology's exchange trades 13,353,384 common shares for pre-funded warrants with a $0.001 exercise price, and the 8-K describes no cash payment to the company.
ALXOEvofem moved the maturity of convertible notes held by Adjuvant to December 1, 2026, and removed some affirmative covenants. The 8-K gives no repayment plan, and the company's year-end cash was $578,000.
EVFMThe offering totals $150,000,000 before fees. The stock has been approved for listing on the Nasdaq Global Select Market under the symbol IAM.
IAMThe company expects approximately $200 million in gross proceeds before fees and expenses. In a later filing it said the placement closed on October 19, 2026.
TRAXThe company will receive $210 million and $203 million in cash, subject to antitrust clearance. The NIH is owed 20% of the first sale.
RARESilo Pharma agreed on October 13, 2026 to buy certain software and related intellectual property from Larry King in exchange for 150,000 shares of common stock. The shares are locked up for up to twelve months, and the 8-K names no underwriter or placement agent.
SILOThe stock purchase comes with a collaboration to engineer three T-cell engager candidates for solid tumors. Closing is subject to customary conditions.
VIRThe company sold shares at $64 and $575 million of 1.50% notes due 2032, adding to $2.5 billion it held at the end of June.
PCVXThe offering totals $45,000,000 before fees. The prospectus discloses a restatement of 2025 financial statements, a material weakness in internal control and going concern doubt.
RTSNTRex Bio priced 8,333,334 shares at $14.00 each, for $116,666,676 before underwriting fees. Eli Lilly, which paid the company a $55.0 million upfront in 2023, has indicated interest in buying shares, but the indication is not binding.
TRXBAquaBounty agreed on October 7, 2026 that all Series A and Series B preferred stock will convert into 8,077,043 common shares by October 30, 2026 at the latest, with the resale shares to be registered.
AQBThe deal includes 5,170,384 shares and pre-funded warrants for up to 1,134,930 shares, with gross proceeds of approximately $50 million before placement agent fees. The company estimates the money and existing cash will fund operations through 2028, but the release gives no cash balance to test that estimate.
RNAValion Bio filed a $100,000,000 shelf registration on October 7, 2026, and the same day agreed to sell 3i $50,000 of Series B preferred and warrants. The public float used for the shelf was based on a $7.75 price, while the last reported sale on October 5 was $2.48.
VBIORange Impact issued 654,434 shares each to MRR CNG and Wicks Building, priced at $0.764, to end two land option deals. Both buyers' $500,000 option fees were counted as the share price, and the 8-K names no adviser or placement agent for the issuances.
RNGETelomir sold 4,843,300 shares at $1.16 each, a 5% discount to its 10-day VWAP, in a PIPE with no warrants. Alexander Capital, L.P. was placement agent, and John Paul DeJoria put in an additional $1.0 million.
TELOHolders exercised older warrants at a reduced $3.866 per share and received new warrants. H.C. Wainwright & Co., LLC acted as exclusive placement agent, and the offering closed on October 5, 2026.
ICUImmunome paid Bristol-Myers Squibb $20.0 million and 4,425,487 shares under Amendment No. 4, which ends its milestone and royalty obligations. The 8-K names no underwriter or placement agent; at June 30, 2026 the company held $217.7 million in cash and equivalents plus $302.3 million in short-term investments.
IMNMA preliminary prospectus dated October 2, 2026 set out a best efforts offering of units with Series D warrants. The deal was later priced to raise about $6.0 million before fees.
SBFMFDA clearance of the SZN-8141 IND satisfies the second closing milestone in Surrozen's March 2025 private placement, which is expected to bring about $95.1 million gross on or about October 20, 2026. First patient dosing is not expected until the fourth quarter of 2026, with initial data in the second half of 2027.
SRZNA holder converted senior secured convertible notes at alternate prices set during the company's strategic review, according to an October 1 filing.
ADGMNOMAD Power Solutions agreed to a secured note with a $6.57 million principal amount, for $6.0 million in gross proceeds. The note matures 12 months after its purchase price date and carries a 9% interest rate.
NMADLantern sold 1,469,725 shares at $1.09 each plus pre-funded warrants for up to 2,200,000 shares. A concurrent private placement of warrants for up to 3,669,725 shares needs stockholder approval before exercise.
LTRNBioStem Technologies has agreed to issue 735,296 shares at $4.08 each in a private placement, with Series A and Series B warrants for the same number of shares at $3.83. The company expects gross proceeds of about $3 million, and about $5.6 million more if all the warrants are exercised for cash.
BSEMCalciMedica filed a prospectus supplement on September 30, 2026 for up to $25,000,000 of stock, sold through H.C. Wainwright & Co., LLC as sales agent for a 3.0% commission. The company has stopped one Phase 2 trial of its lead drug and now plans a Phase 2b step first.
CALCBeyondSpring has set up an at-the-market program through Citizens for up to 9,200,000 ordinary shares, capped at $11,942,800 by its public float limit. The prospectus supplement is dated September 29, 2026, and the same day the company agreed to sell its Chinese subsidiary to Biolin Investment Limited.
BYSICuprina closed the sale of 648,373 more Class A shares at $1.15 after the underwriter exercised its over-allotment option in full. Total gross proceeds reached about $5,716,491, and R. F. Lafferty & Co., Inc. was the sole book-running manager.
CUPRThe company is selling 11,363,637 shares through J.P. Morgan. Proceeds will fund development of its CAR-T candidate NXC-201.
IMMXImunon will exchange $1,200,000 of a Streeterville note for 120 Series B preferred shares that cannot convert into common stock but carry an 8% return. Cash and cash equivalents were $6.9 million at June 30, 2026.
IMNNPyxis Oncology is selling 36,047,919 shares at $2.900 and pre-funded warrants, with common warrants at $3.50 that cannot be exercised until stockholders approve more authorized shares. Its auditor's report on the 2025 financial statements carries a going-concern warning.
PYXSHolders exercising 3,216,928 existing warrants receive 6,433,856 new warrants that cannot be used until shareholders approve more authorized shares.
SLXNADARx Pharmaceuticals sold 26,250,000 shares at $17.00 in its IPO for about $446.3 million gross, and AbbVie bought 5,255,542 shares in a concurrent private placement worth about $89.3 million. The company had net losses of $46.4 million in 2024 and $73.1 million in 2025.
ADRXJaguar issued 481,584 shares to Streeterville Capital in exchange for a $3,400,000 cut to a note first sold in 2021. The company reported about 1,945,542 shares outstanding as of September 25, 2026.
JAGXViking sold shares at $35 and 2% notes due 2032 that convert at about $50.75. Both deals were upsized from $200 million each, and full exercise of the underwriters' options lifted gross proceeds to $575 million.
VKTXThe company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain.
NANOThe sales raised $0.48 million, and anti-dilution terms cut the exercise price of the August 2026 Series I Warrants to $0.51.
MBRXMapLight's resale prospectus lets the investors in its $150.0 million August placement sell up to 13,181,055 shares. The company receives no proceeds from those sales.
MPLTLeonaBio said its Series A common warrants became exercisable on September 18, 2026 and remain exercisable until October 19, 2026, with about $146.2 million of cash if fully exercised.
LONAThe agreement with the Rain Foundation was subject to shareholder approval. The company says it will not complete the placement or seek that approval.
ENLVIambic Therapeutics, Inc. filed a Form S-1 on September 21, 2026. The cover leaves the share count and price range blank.
IAMDawson James Securities is sole placement agent for the offering, priced at $1.46 per share under Nasdaq at-the-market rules.
TCRTBioStem (Nasdaq: BSEM) may sell shares to Roth Principal Investments over up to 36 months at a 3.0% or 5.0% discount to average price. The company pays a $400,000 cash commitment fee.
BSEMElectra Therapeutics sold 23,333,334 shares at $15.00 in its initial public offering. The final prospectus repeats the auditor's going concern paragraph from the registration statement.
ETRANasus Pharma can sell up to $8,500,000 of shares through BTIG but is not obliged to. Its June 30, 2026 balance sheet held $11,904 thousand in cash, restricted cash and short-term deposits, and its prospectus supplement lists substantial doubt about going concern among its risks.
NSRXRetension Pharmaceuticals, a Falls Church, Virginia developer of a hypertension drug, filed a Form S-1 on September 18, 2026. The preliminary prospectus leaves the share count and price blank, and its 2025 financial statements have been restated.
RTSNTRex Bio filed for a Nasdaq IPO on September 18, 2026. Eli Lilly, which signed a research collaboration with the company in 2023, has indicated interest in buying shares, but the indication is not binding and the price range and share count are still blank.
TRXBThe 1.50% notes due 2033 convert at about $139.84 a share, a 27.5% premium to the Sept. 17 close. Part of the proceeds repurchases 2027 and 2028 notes and pays for capped calls.
HALOThe deal needs Xenetic stockholder approval. Pro forma, current Xenetic holders would own approximately 15.0% and Santersus holders approximately 85.0%.
XBIOJaguar Health exchanged a convertible note and Series Q preferred shares for common stock in September 2026, and issued 535,000 common shares plus a pre-funded warrant to acquire the Napo Therapeutics shares of a minority holder.
JAGXTyra Biosciences priced 9,079,000 common shares and pre-funded warrants for 9,078,529 more, expecting about $400.0 million gross at $22.03 a share. The company had $73.8 million of cash at June 30, 2026, and a 2025 net loss of $119.9 million.
TYRAAll TransCon licenses in metabolic and cardiovascular disease, including once-monthly semaglutide, revert to Ascendis with no continuing financial obligations.
ASNDNOVO BHolders exercised 572,179 existing warrants for cash and received new warrants for 858,269 shares at $5.02 per share. WallachBeth Capital acted as financial advisor, and the closing was expected on or about September 14, 2026.
TNONBioVie agreed with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market program, with a 3.0% commission on gross proceeds.
BIVIRegentis Biomaterials reported on September 11, 2026 that it had about $9.0 million in cash at June 30, 2026, after a $6.5 million private placement in June. It says it has repaid its debt entirely, and it now expects the U.S. pivotal trial of GelrinC to finish enrolling at about year end 2026.
RGNTLexaria Bioscience cut the exercise price on 453,969 existing warrants to $12.92 a share, for about $5.9 million in gross proceeds. In return it issued two new warrant series, each for the same number of shares, at $12.67.
LEXXThe warrants will be exercised at $12.92 per share for gross proceeds of about $5.9 million, with H.C. Wainwright & Co. as exclusive placement agent. Holders receive new Series A and Series B warrants at $12.67.
LEXXThe peptide drug developer will fund repurchases from cash and royalty income. It held $849.5 million at June 30, before $275 million in Takeda payments due in the fourth quarter.
PTGXA September 2026 investor presentation lists a $1.0M July 31 private placement, about $1.0M of cash at June 30, 2026, and a runway the slide dates to early October 2026.
SXTPThe board approved the program after Keros received a development milestone payment under its elritercept license with Takeda. The program does not oblige Keros to buy any shares.
KROSNutriband says its operations will fund the next year and that going-concern doubt is gone, but revenue and spending both fell in the quarter and the company still burned cash.
NTRBADARx Pharmaceuticals filed an S-1 for a Nasdaq IPO under ADRX, with five banks on the cover and the share count and price range left blank. Its net loss was $73,088 thousand in 2025, and it holds a $335.0 million upfront payment from AbbVie.
ADRXPolyrizon closed about $4.0 million from a registered direct offering and a concurrent private placement sold to one institutional investor, at $12.00 per unit. Aegis Capital Corp. acted as placement agent, and its fee took 8% of the registered portion.
PLRZLoss after tax attributable to owners was 79,304,563 for the year ended 30 June 2026, up from 61,434,165. Revenue included $14.6 million from licensing partner Dr Reddy's.
IMMThe private placement brings about $5.0 million at closing, with a further $5 million tranche of warrants, and Ladenburg Thalmann & Co. Inc. acts as placement agent.
INBSTenon Medical agreed to sell 597,610 shares, or pre-funded warrants, to an institutional investor, with warrants for up to 1,058,517 more shares. WallachBeth Capital LLC is the exclusive placement agent.
TNONBioLineRx sold 1,348,921 ADSs at $2.78 each and issued warrants on 2,023,382 more ADSs. It also amended older warrants on 277,273 ADSs and cut its at-the-market facility to zero.
BLRXQuoin agreed to sell 6,305,300 ADSs or pre-funded warrants at $4.88 and warrants for up to 3,152,650 ADSs, for about $30.8 million at closing. The same day it reported interim results from six patients, and its 10-K carries a going-concern warning.
QNRXCan-Fite BioPharma's shelf sets a ceiling of $100,000,000, but the at-the-market sales agreement with H.C. Wainwright & Co., LLC covers only $1,065,000, a limit set by its public float.
CANFElectra Therapeutics filed a Form S-1 on August 28, 2026, and the cover leaves the share count and price range blank. Its auditor's report includes a going concern paragraph, and the company says its cash may not cover the next 12 months.
ETRAThe 1.875% notes due 2032 carry an exchange price of about $355.24, a 42.5% premium to the Aug. 26 close. The offering was upsized from $1.0 billion.
JAZZOptimi can sell shares to Seven Knots, LLC at its discretion, up to US$2 million per draw. It issued a US$1.5 million convertible note as a commitment fee.
OPTILeonaBio said it enrolled the 500th subject in its ELAINE-3 trial of lasofoxifene, an announcement that also sets a date used in the exercise terms of its Series A warrants.
LONAA Form D filed August 26, 2026 reports $1,650,000 sold to eight investors, while the August 14 agreements covered $1.35 million. The shares carry registration rights.
TTRXImmatics agreed to sell 12,945,916 ordinary shares at $8.69, plus pre-funded warrants for 4,315,304 shares, for expected gross proceeds of $150 million. Its 2025 net loss was €196.4 million, after net income of €15.2 million in 2024.
IMTXThe agreements are dated August 25, 2026, and priced at $0.05 per share. The filing names no underwriter or placement agent.
HEPAArbutus filed a Schedule TO on August 24, 2026 to start an issuer tender offer for up to US$230 million of its common shares, paid in cash. The filing points to an Offer to Purchase dated the same day, and it does not state the start or expiry dates in its own text.
ABUSSkye Bioscience's equity line with a Redmile affiliate covers up to $22,000,000 and requires purchases of up to $2,000,000 a month once it starts. The line is reduced if the PIPE exceeds $103,000,000 and falls away at $125,000,000.
SKYEMoleculin can now sell up to $19,700,000 under its at-the-market program, weeks after a July deal with warrants on 37,130,001 shares. The trial figures it cited are blinded and preliminary, drawn from 62 patients.
MBRXInsiders and large holders sold Veradermics stock in August, with a resale prospectus dated August 14 covering selling stockholders. The company receives none of the proceeds from those sales.
MANEGossamer Bio's private placement of up to $250 million opens with $25.0 million at a first closing. A $125.0 million second closing depends on FDA acceptance of its seralutinib filing, and warrants that could add about $100.0 million depend on FDA approval.
GOSSTD Cowen is the sales agent for up to $500,000,000 of common stock under a sales agreement that sits inside a $1,000,000,000 shelf. The filing puts the outstanding count at 61,069,887 shares on June 30, 2026.
ORKAUroGen gets an option on IntraGel's TumoCure for advanced head and neck cancer and agrees to invest up to $7,000,000 in IntraGel's equity. The 8-K gives no clinical data, no option fee and no exercise deadline.
URGNTuHURA Biosciences' stockholders approved on August 18, 2026 the issue of 1,878,287 shares to its lender, Parkview Holdings One LLC, as a fee for a $50 million revolving credit facility. The company's cash stood at $995,977 on June 30, 2026, according to its quarterly report.
HURAInnate Pharma is issuing new shares at a fixed €1.70 each through Stifel and BTIG. Year-end cash fell to €28.1 million at December 31, 2025, from €66.4 million a year earlier.
IPHAmylyx's final supplement prices 14,090,000 shares at $35.500 for $500,195,000 before costs, above the $350,000,000 in the first filing. The company announced Phase 3 topline results the same day.
AMLXSciSparc put in C$2.7 million, half the total, and says it will hold approximately 44.6% of NeuroThera afterward. NeuroThera plans to use the money for general working capital.
SPRCNTLXDermata Therapeutics agreed to sell 2,293,608 shares, or pre-funded warrants, at $1.46 per share, with Series E and Series F warrants attached. Gross proceeds are expected to be about $3.4 million before offering expenses.
DRMACash and cash equivalents reached CAD 307,828,515 at June 30, 2026, after a January 2026 public offering at US$90 a share. Over the nine months the company used CAD 23,402,489 in operations and reported no revenue.
DRUGDaré Bioscience sold 4.38M shares at $1.37 and gave buyers two warrant series covering 8.76M more, while Nasdaq reviews its listing and cash runs into Q4.
DAREAdlai Nortye reports $231.9 million in cash and short-term investments at June 30, 2026, up from $8.1 million six months earlier, after two private placements of $140 million and $150 million before fees, and it has de-prioritized AN4005 as a monotherapy.
ANLSales run through Leerink Partners under an agreement dated June 28, 2024. The commission is up to 3.0% of gross proceeds.
IFRXThe company says its June 2026 private placement brought in about $7.6 million in net proceeds and that its cash should fund operations through the second quarter of 2027.
BJDXEnsysce Biosciences said the Cy Biopharma acquisition closed on August 6, 2026, with private placement financings of $38.6 million and cash runway into late 2027.
ENSCMapLight agreed to sell 9,197,887 voting shares at $11.38 and pre-funded warrants for 3,983,168 more shares, for about $150.0 million gross before fees.
MPLTMapLight reported $351.3 million in cash and investments at June 30, 2026 and cited funding through 2028. It also agreed to a private placement of about $150.0 million at $11.38 a share. Six-month operating cash use was $96.0 million.
MPLTThe best-efforts deal closed August 13, 2026. Silexion also converted $750,001 of debt owed to its former SPAC sponsor into shares at the offering price.
SLXNThe warrant covered 1,192,207 shares at $5.03. Because GEM used the cashless option, Turn received no cash and issued fewer shares than the warrant allowed it to buy.
TTRXAptevo Therapeutics (Nasdaq: APVO) closed deals that cut warrant exercise prices to $4.03 per share and sold shares or pre-funded warrants in a private placement. Roth Capital Partners was placement agent.
APVONervGen's cash rose to C$86,789,698 after a May 2026 offering of 24,000,000 units. Its warrant liability climbed to C$68,625,899, and a related party bought 800,000 of the units.
NGENProQR raised about $59.2 million in June, through a $50.0 million underwritten registered direct offering and a $9.2 million private placement to Eli Lilly and Company. The release names no underwriter, and says cash of €117.1 million covers runway into mid-2028.
PRQRThe company can sell up to $50.0 million of common stock to one institutional investor, and the same day it amended a Series H preferred stock agreement with that investor.
FEEDRepurchases run no later than December 31, 2026. The company expects year-end 2026 cash and financial investments of EUR 1.975 billion to EUR 2.050 billion, including the buyback.
LKFTPharvaris reported €318 million of cash at June 30, 2026, after a $132.3 million underwritten offering it closed in May. The company says the money extends its runway into 2028, while its quarterly loss reached €47.8 million and its key pivotal trial has yet to report.
PHVSVogenx priced 6,250,000 shares at $13.00, for $81,250,000 before underwriting discounts. The prospectus shows $251 thousand of cash at March 31, 2026 and a going-concern warning.
VOGXThe company extended its runway into the second half of 2028. Lilly's stake carries no rights to the ABS-201 antibody.
ABSIThe upsized offering priced at $13.50 per ADS a day after the SANRECO results, adding to $72.1 million in cash at the end of June.
SLNVeradermics reported $819.9 million in cash and securities at June 30 and says the money lasts into 2030. That runway depends on Phase 3 readouts, the first of them due in the second half of 2026.
MANEA later announcement prices 17,435,897 common shares and pre-funded warrants for 3,076,926 shares, for expected gross proceeds of about $200.0 million. The offering is expected to close on August 14, 2026.
ABCLTango Therapeutics filed to sell up to $400,000,000 of stock through Leerink Partners, replacing a $100,000,000 program of which about $64,389,566 had been sold. Its early response rates come from a small group of patients treated in combination.
TNGXGuggenheim Securities may act as agent or principal and is entitled to a 3.0% commission. The last reported sale price on August 7, 2026 was $42.39 per share, and the supplement puts dilution to new buyers at $37.68 per share.
COGTGlucotrack amended its July 14, 2026 common stock purchase agreement with White Lion Capital, LLC, agreeing to issue 2,505,513 commitment shares and to pay a true-up amount if the commitment fee price falls below the minimum price.
GCTKBlossomHill priced 9,375,000 shares at $16.00 for $150,000,000 before costs, with delivery expected on or about August 10, 2026. The auditor's report on the 2025 financial statements includes a going-concern paragraph.
BLSMCorbus can sell up to $127,500,000 of common stock through Jefferies LLC, which earns a fixed 3% commission on each share. At the $9.40 price the filing uses, new buyers would see $2.46 a share of immediate dilution.
CRBPThe offering totals $345,600,000 before underwriting discounts, and the company's auditors have raised going-concern doubt.
LTGOThe holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter end.
ROIVThe Jefferies program replaces a November 2025 prospectus and has raised about $257.7 million in net proceeds to date. The filing came the day the company reported second-quarter results.
SRRKAn April stock sale lifted cash, and Celldex guides to funding through 2028. Its finance chief of nine years plans to leave by March 31, 2027.
CLDXE.F. Hutton & Co. is the exclusive placement agent, and the offering is expected to close on August 7, 2026.
ISPCSecond-quarter net loss was $19.9 million. SpyGlass says its IPO proceeds and cash will fund operations through 2028 and that it will need substantial additional funding after that.
SGPGKOSThe merger agreement signed July 31, 2026 also provides milestone payments of up to $350,000,000. Closing needs Hart-Scott-Rodino clearance, and Tarsus expects to complete the deal in 2026.
TARSCash of €252.0 million compares with a six-month net loss of €31.0 million and €29,917 thousand used in operating activities. The release gives no efficacy figures for either of the two drugs.
AGMBThe at-the-market program would run through Leerink Partners as sales agent. The company's stock last sold at $11.59 per share on August 5, 2026.
ARTVBraveheart Bio's final prospectus, dated August 5, 2026, prices 21,250,000 shares at $18.00 each. Net proceeds are estimated at $351.2 million, and the company's accumulated deficit was $80.3 million at March 31, 2026.
BRVEThe April offering sold 6,527,779 shares at $18.00. The interim report does not name the underwriters, and the six-month loss rose to $34,113 thousand.
GHRSOculis sold 2,250,000 shares under its ATM program for CHF 47,775 thousand in the first half of 2026. Cash and cash equivalents fell to CHF 61,614 thousand at June 30, 2026.
OCSRelay Therapeutics amended its stock sales agreement on August 6, 2026 to add $212,978,049 of at-the-market sales, raising the program to $462,978,049. The prospectus puts immediate dilution at $14.22 a share for investors who buy in the offering.
RLAYSolid Biosciences filed a prospectus supplement for up to $200,000,000 of at-the-market stock sales through Jefferies, replacing a prior $85,000,000 program. The filing says buyers would face dilution of about $4.30 per share at an assumed $8.73 price.
SLDBArcus and AstraZeneca will stop PACIFIC-8 in stage III lung cancer. Second-quarter cash was $775 million, with runway guided to at least the second half of 2028.
RCUSGILDAZNThe offering totals $289,000,000 before fees. The shares have been approved for listing on the Nasdaq Global Market as ATTO.
ATTO60 Degrees sold shares at $1.74 for approximately $1.0 million gross, with H.C. Wainwright & Co. as exclusive placement agent, after its annual report carried a going-concern warning.
SXTPCAMP4 Therapeutics sold 10,756,498 shares and pre-funded warrants for 21,925,368 shares on August 3, 2026, after the trigger for the second closing was satisfied.
CAMPThe company says it is no longer subject to a Form S-3 sales limit. It had not sold any Class A shares under the program as of August 4, 2026.
OKURTyra Biosciences has sold the full $150,000,000 under its May 2025 at-the-market agreement and has raised the ceiling to $250,000,000. The filing also shows a 2025 net loss of $119.9 million and cash used in operations of $95.1 million.
TYRAThe agreement allows up to $25 million of Series D convertible preferred stock, and the first tranche closed July 31, 2026.
ALZNOPKO Health, a longtime shareholder, buys 5,474,053 shares at $0.9134 each in a private placement with no warrants attached.
COCPOPKThe senior secured notes mature July 30, 2031. Perceptive also received a warrant for up to 3,500,000 American Depositary Shares at $1.9314 each.
AUTLStoke filed a $200,000,000 at-the-market supplement with Cantor Fitzgerald & Co. as sales agent, which can be paid up to 3.0% of gross proceeds. It replaces an earlier supplement under which the company sold about 4.7 million shares for net proceeds of $146.4 million.
STOKLadenburg Thalmann & Co. Inc. is the exclusive placement agent, and the deal includes warrants to buy up to 1,310,890 shares.
NUWEHolders of existing warrants agreed to exercise at $1.571 per share in exchange for new warrants at $1.56. Maxim Group LLC is the exclusive placement agent.
CODXAgreements dated July 31, 2026 cover 61,100,000 shares at $0.05 per share. The offering closed on August 3, 2026, and the filing names no underwriter.
HEPAApnimed priced 12,000,000 shares at $16.00 for $192,000,000 before fees. The company has no approved drug, a secured term loan, and a going-concern warning in its prospectus.
APMDNorthwest Biotherapeutics signed a $4.9 million convertible note with a Yorkville fund on July 29, 2026. Net proceeds after original issue discount, a facility commitment fee and expenses are $4,655,000.
NWBOThe Danish investor sold 1.6 million shares in open-market trades at $12.00 to $15.00 and reported 2,086,622 shares left, about 4.9%.
MPLTThe company sold 21,045,000 shares at $20.50 in July and expanded a loan facility to $400 million as it prepares a possible Duchenne launch.
DYNThe company agreed to sell 618,682 units at $2.585 per unit, including shares to its founder, chairman and an officer, and the common warrants need stockholder approval.
HCWBOn July 29, 2026, RA Capital Healthcare Fund exchanged 18,030,000 Inhibikase common shares for a pre-funded warrant on the same number of shares. The warrant carries a 9.99% ownership limit, and the filing does not say why the exchange was made.
IKTInventiva reported preliminary first-half 2026 figures showing €166.1 million in cash and €67.8 million in short-term deposits. The company says current cash does not cover operations for the next 12 months.
IVAThe company is selling 3,577,560 shares and pre-funded warrants for up to 715,513 shares to institutional investors. The deal is expected to close on or about July 30, 2026, and the 2025 10-K filed in March 2026 shows net loss of $25.2 million for the year.
LBRXThe securities purchase agreement covers 37,812 shares of Series F convertible preferred stock with an initial conversion price of $0.9767 per share.
ONCOBVF Partners-affiliated funds are among the buyers and gain the right to name two directors. Entera says it will use the money to support a Phase 3 study of EB613.
ENTXScribe sold 8,580,000 shares at $15.00 with a going concern warning in its prospectus. The company had $49.7 million in cash and marketable securities at March 31, 2026, against $40.5 million in outstanding indebtedness.
SCTXBTIG, LLC ended the 2020 at-the-market sales agreement with Matinas BioPharma, effective July 23, 2026, and the company says it owes no termination penalties.
MTNBMannKind sold 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88. The company names a $45.0 million contingent value rights payment, triggered by an FDA approval, among the uses of the money.
MNKDThe underwriters bought 4,696,102 additional shares on July 23, 2026, for about $1.5 million in gross proceeds. Lake Street Capital Markets, LLC acted as representative of the underwriters.
AEONRadiopharm amended its at-the-market program to $9,300,000 on July 23, 2026. The next day it announced a $4.1 million registered direct offering at $3.16 per ADS, below the $4.29 last sale price on July 21.
RADChina Pharma Holdings, Inc. priced a registered direct offering of 2.5 million common shares at $2 per share, for gross proceeds of $5 million before placement agent fees and other expenses. FT Global Capital, Inc. is the exclusive placement agent.
CPHISunshine Biopharma Inc. signed an at-the-market sales agreement with Aegis Capital Corp. under which it may sell up to $4,000,000 of common stock, with Aegis as exclusive sales agent.
SBFMThe company says it raised approximately $25 million in the fiscal year ended March 31, 2026. It says its cash funds the planned Phase 3 trial of urcosimod.
OKYOBlossomHill's S-1 leaves the share count, the price range and the proceeds blank. The prospectus also says the auditor's report on the 2025 financial statements carries a going-concern paragraph.
BLSMLatigo Biotherapeutics, Inc. filed a Form S-1 on July 17, 2026. The filing leaves the share count and price range blank, and the auditors have raised going-concern doubt.
LTGOVivoSim Labs agreed to sell 4,705,883 shares and warrants to one healthcare investor, with A.G.P./Alliance Global Partners as sole placement agent.
VIVSBio-Path reports two small share sales under its Regulation A offering and an advisory engagement to find a buyer, partner or licensor.
BPTHHelus Pharma sold 10,309,280 shares at US$4.85 in an underwritten offering that closed on June 25, 2026. The proceeds are meant partly for a Phase 3 depression program whose data are not due until the fourth quarter.
HELPREGENXBIO launched a $100 million stock offering on July 16, 2026 at $9.00 a share, below the $11.20 close. Its own preliminary estimate puts cash, cash equivalents and marketable securities at about $105.5 million on June 30, down from $150.5 million on March 31.
RGNXBraveheart Bio, Inc. filed a Form S-1 on July 15, 2026 for an initial public offering on The Nasdaq Global Market under the symbol BRVE. The preliminary prospectus leaves the share count and price blank, and names Goldman Sachs & Co. LLC and Jefferies as joint bookrunners.
BRVEProQR is registering 3,030,303 shares for resale by a holder the prospectus calls Ginkgo, issued in April 2026 under a share purchase agreement tied to a services contract. ProQR receives none of the proceeds, and the prospectus gives no per-share price for the shares.
PRQRVogenx filed a Form S-1 on July 15, 2026 for an initial public offering with the share count and price still blank. The filing reports $251 thousand of cash on March 31, 2026, and its financial statements carry going-concern doubt.
VOGXMorgan Stanley, Jefferies, Cantor Fitzgerald and Oppenheimer are the representatives of the underwriters. The offering is expected to close on July 16, 2026.
QTTBAttovia Therapeutics, Inc. filed a Form S-1 on July 14, 2026. The cover leaves the share count and price range blank.
ATTOThe offering was priced at $0.3221 per share and accompanying warrants. Lake Street Capital Markets, LLC is sole bookrunner, and Laidlaw & Company (UK) Ltd. is lead manager.
AEONCumberland will pay a $1.50 special dividend and has authorized up to $5 million of buybacks. The board acted after the Apotex sale produced more net cash than the company had projected.
CPIXErasca's final terms are 31,428,572 shares at $17.50, a total of $550,000,010.00, above the $500,000,000 first announced. Its two clinical-stage programs are early, and the annual report shows a net loss of $124.5 million for 2025.
ERASCitizens JMP Securities, LLC may sell up to $5,575,709 of Traws common stock under a July 10, 2026 prospectus supplement, the amount the company's current baby shelf limit allows.
TRAWSilo agreed to sell 619,965 shares and warrants at $6.452 per share, with H.C. Wainwright & Co. as exclusive placement agent. The company expects about $4 million upfront.
SILOCue will sell 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for gross proceeds of about $50.0 million. Cormorant Asset Management led. The 8-K also reports RSU grants to officers and directors.
CUEApnimed, Inc. filed a Form S-1 with a preliminary prospectus dated July 10, 2026. The cover leaves the share count and price range blank, and the company has no approved drug yet.
APMDCue Biopharma is selling 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for about $50.0 million in gross proceeds. Its release says the lead candidate is advancing toward Phase 1, while its annual report calls that candidate preclinical.
CUECanaccord Genuity and Roth Capital Partners are the sales agents under a June 26, 2026 agreement, for a 3% commission. The supplement puts net tangible book value at $0.97 a share against a $3.37 reference price.
NAGEBone Biologics sold pre-funded warrants for 2,112,677 shares at a combined $1.419 each, with Series F and G warrants at $1.42, through H.C. Wainwright & Co. Net proceeds were about $2.7 million, and the 10-K carries a going-concern warning.
BBLGSemnur, a majority-owned subsidiary of Scilex, said iHolding Group LLP would buy $100,000,000 of newly issued common stock at an expected $10.00 per share. The proposal remains subject to due diligence and definitive agreements.
SMNRMeiraGTx will receive up to $400 million from Oberland Capital, starting with $135 million that includes $125 million of royalty funding and a $10 million equity investment. The release does not state the cap multiple on the royalties or the price of the new shares.
MGTXMaxim Group LLC is sole placement agent for 5,633,009 shares or pre-funded warrants, each sold with a warrant for the same number of shares.
AEMDThe index change took effect after the U.S. market close on June 26, 2026. A Form F-3 filed on July 13, 2026 replaces an older shelf and includes a $50,000,000 at-the-market program.
HYFTThe CEO and the principal financial officer paid for the shares by cancelling amounts the company owed them, including personal cash advances. IGC Pharma paid no cash.
IGCMetaVia filed a prospectus supplement for up to $4,000,000 of common stock under its at-the-market sales agreement with Ladenburg Thalmann & Co. Inc., dated November 6, 2025.
MTVAHolders of warrants for 2,790,340 shares exercised after the price fell from $2.86 to $1.60 and received new warrants for 5,580,680 shares. Roth Capital Partners acted as financial advisor.
CELZPyxis Oncology agreed to sell 19,600,153 shares at $2.551 and warrants at $3.289 to investors led by BVF Partners L.P. The press release says the upfront money extends cash into the second quarter of 2027, while the company's annual report carried a going-concern warning and said cash would fund operations only into the fourth quarter of 2026.
PYXSThe company signed an Open Market Sale Agreement with Jefferies LLC on July 2, 2026. Jefferies is entitled to a commission of up to 3.0% of gross sales.
ENTAScribe Therapeutics filed an S-1 on July 2, 2026 with blank share and price terms. Management and its auditor have raised substantial doubt about its ability to continue as a going concern.
SCTXThe 7% preferred converts at $137.79 a share and is aimed at supporting present and upcoming launches. $933.9 million was funded at close.
BBIOCadrenal (Nasdaq: CVKD) received gross proceeds of approximately $3.0 million from one institutional investor. Warrants could add about $5.8 million if exercised in full for cash, the company says.
CVKDThe offering is priced at $0.38 per share and common warrants. WallachBeth Capital LLC is the sole placement agent, and part of the proceeds will repay convertible notes.
TNONAbivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results.
ABVXThe HAE drugmaker will stop internal drug discovery and look outside for new programs. A later 8-K/A put severance at $6.2 million to $7.5 million, and a state WARN notice listed 47 jobs at the site.
BCRXSoligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,500,000.
SNGXThe private placement closed June 25, 2026, with Univest Securities, LLC as placement agent. The shares carry an 18.0% annual dividend and a $1.03 conversion price.
AQBVoting results filed June 25, 2026 show resolutions 13 to 24 carried with 95.25% to 99.73% of votes cast. Resolution 30, a savings-plan share issue, drew 14.81% support, yet the filing labels it carried.
ALCLSThe offering followed interim phase 1 data for ABS-201. Proceeds fund the antibody's hair loss and endometriosis programs.
ABSIInvestors agreed to buy 18,673,429 units at $0.8033 or $0.8032. Series A and B warrants could add up to approximately $34 million if fully exercised for cash. Closing is expected on or about June 25, 2026.
CALCThe sales agreement dates to 2019 and was amended in 2022 and 2023. TD Cowen can receive up to 3.0% of gross proceeds, and the prospectus lists 100,200,000 shares issued in April at $2.00 a share.
ALLODefinium sold 20,588,236 common shares at $34.00, or $700,000,024 before discounts, on the same day it reported that its Emerge depression trial met its primary endpoint. The prospectus supplement names eight underwriters, and its underwriting terms name no counsel.
DFTXuniQure filed a $150,000,000 offering on June 22, 2026 and priced an upsized deal on June 23. The FDA has said its Huntington's data are not sufficient evidence for a marketing application, and the proceeds are partly earmarked for a launch.
QUREThe sale agreement supplement covers up to $89,650,167 of stock sold through Jefferies. Iovance's last reported sale price was $3.93 on June 17, 2026, and its 2025 net loss was $391.0 million.
IOVAKardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern.
KARDThe Standby Equity Purchase Agreement lets PRF sell up to $15.0 million of shares over 36 months at 97% of recent prices. Its 2026 going-concern paragraph and $3.1 million year-end cash sit beside the new line.
PRFXRedhill Biopharma agreed on June 18, 2026 to sell 8,571,429 ADSs at $0.70 each with two series of warrants. The upfront money is about $6 million, and the warrants add about $13.4 million only if they are exercised for cash, which the company says is not assured.
RDHLThe offering totals $225,995,000 before underwriting discounts. Underwriters hold a 30-day option for 1,155,000 more ADSs, and closing was expected on June 23, 2026. The shares priced below the last sale price of $33.52.
LEGNAlvotech priced 22,666,667 shares at $3.750, below its $4.24 Nasdaq close on June 15, and a private placement of 17,826,666 shares to European investors is set to add about $66.85 million.
ALVOParabilis Medicines (Nasdaq: PBLS) sold shares to Regeneron at 90% of the $20.00 IPO price under a Stock Purchase Agreement dated June 9, 2026. The placement closed June 11, 2026.
PBLSThe final terms total $399,998,279.17 in shares and pre-funded warrants before underwriting discounts. The offering was expected to close on or about June 15, 2026.
ELVNThe sale at $0.72 per share closed on June 10, 2026 under Regulation S, and the filing names no underwriter, placement agent or financial advisor.
BGMSParabilis Medicines priced 33,500,000 shares at $20.00 each, and Regeneron agreed to buy $75.0 million of stock at 90% of the IPO price, as the company's net loss reached $145,889 thousand in 2025.
PBLSThe prospectus supplement adds $2,425,000 of common stock to an at-the-market agreement with H.C. Wainwright & Co., LLC, following $4,483,711.04 already sold under it.
ENVBBGM Group sold 200,000,000 Class A ordinary shares at US$0.06 each, with warrants for up to another 200,000,000 shares, for gross proceeds of US$12,000,000. The private placement closed on June 8, 2026.
BGMLadenburg Thalmann & Co. Inc. was sole book-running manager, and the deal included Series C warrants for up to 60,000,000 shares.
NUWEBioNTech is buying back American Depositary Shares worth up to USD 1.0 billion, with the buyback period running from June 8, 2026 to May 6, 2027. The program rests on a May 17, 2024 shareholder authorization capped at 24.9 million shares, and a credit institution the company has mandated runs the purchases.
BNTXThe June 5, 2026 deal sold 3,300,000 shares at $0.45 each, with warrants to buy up to 4,455,000 more shares. The filing names no underwriter or placement agent.
AWHLSolid Biosciences filed a prospectus supplement on June 5, 2026 that adds holders who bought shares from existing selling stockholders. Several holders in the table are offering their entire stake, and the company says it does not know when or in what amounts they will sell.
SLDBValneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it will receive no proceeds from the resale.
VLABriaCell sold 1,449,300 common shares at $3.25 in a best efforts offering for gross proceeds of $4.71 million. ThinkEquity LLC was sole placement agent, with a 7.5% cash fee and warrants for 72,465 shares, and the company's 10-K carries a going-concern warning.
BCTXMineralys sold 5,660,378 shares at $26.50, below the $28.85 last sale on June 2, 2026. The proceeds fund part of a $200.0 million upfront payment to buy back a royalty owed to Tanabe Pharma Corporation.
MLYSCalidi Biotherapeutics replaced a May 6 warrant for up to 17,391,304 shares at $0.23 with one that cannot be exercised until stockholders approve it. The minimum vesting amount doubles to $1,000,000 and the vesting deadline moves to September 30, 2026.
CLDISoligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,956,000.
SNGXENDRA agreed on May 27, 2026 to sell 578,387 shares or prefunded warrants, with common warrants for up to 1,156,774 shares, through sole placement agent Lucid Capital Markets, LLC.
NDRAPrices ran from $3.70 to $4.10 a share depending on commitment size. MStone Partners, the largest holder, bought $360,000 of stock.
PLYXSol-Gel's first-quarter 2026 report shows $52.8 million in cash and securities at March 31 after a March offering of about $33.1 million, with revenue of $0.1 million and a net loss of $3.7 million. The company says the funds support operations into 2028.
SLGLAptevo and Niowave agreed to a 50/50 collaboration to develop up to three radiopharmaceutical oncology programs, with Niowave making an at-the-market equity investment at closing.
APVOMinerva signed a sales agreement with Leerink Partners LLC for up to $75.0 million of common stock, and its filing also says the roluperidone Phase 3 relapse phase now runs 52 weeks.
NERVKardigan filed an S-1 for an IPO that would list on the Nasdaq Global Market as KARD. The filing leaves the share count and price range blank, reports $287.1 million of cash and investments, and still says there is substantial doubt about its ability to continue as a going concern.
KARDFOXO settled amounts owed to J.H. Darbie & Co., Inc. with preferred stock and $175,000 in installments. Its majority holder approved a reverse split at a ratio of 1:1,000 to 1:10,000.
FOXOThe company priced 2,846,975 units at $1.405 each to a group of healthcare investors, and the warrants are exercisable at $1.28 per share.
HCWBThe offering totals US$15,000,000 before fees. Optimi has been approved to list on the Nasdaq Capital Market under the symbol OPTH.
OPTIThe F-3 caps the Wainwright ATM at $824,331 because the public float is below $75.0 million. The filing puts the float at $4.9 million, and the ADS last traded at $3.78 on May 18, 2026.
PPBTParabilis Medicines filed its IPO registration on May 19, 2026, with a $75.0 million Regeneron private placement tied to a collaboration, while its net loss grew to $145,889 thousand in 2025.
PBLSRegencell Bioscience agreed on May 19, 2026 to sell 985,222 ordinary shares at $20.30 each in a registered direct offering, about $20.0 million gross. Univest Securities, LLC is the sole placement agent and is also buying shares for its own account.
RGCThe reasonable best efforts offering of 12,000,000 common units at $0.50 per unit is expected to close on or about May 19, 2026, with Aegis Capital Corp. as exclusive placement agent.
SBFMWarrant holders paid approximately $1,963,967 in gross proceeds on May 12, 2026 under an incentive program. The company also raised its stockholder meeting quorum to one-third to match Nasdaq rules.
CNXUThe earlier program bought back shares at an average price of $24.36 for $102.3 million. Zymeworks had about 73.0 million common shares outstanding as of May 13, 2026.
ZYMEDermata Therapeutics said its at-the-market facility produced $2.0 million of net proceeds in the first quarter of 2026. Cash was $6.9 million at March 31, 2026, and the company expects its resources to fund operations into the first quarter of 2027.
DRMAWhitehawk agreed to sell 4,330,866 shares at $3.92 and 17,991,021 pre-funded warrants in a PIPE financing. The company expects gross proceeds of about $87.5 million and a May 14, 2026 closing.
WHWKAllogene had $266.9 million in cash and investments at March 31, 2026, after an April offering with $200.4 million gross proceeds. Its first-quarter net loss was $42.6 million, and its key ALPHA3 comparison rests on 12 patients per arm.
ALLOA $30.1 million gain on warrant liabilities turned a $20.8 million operating loss into $9.2 million of net income.
GUTSThe company sold $250 million of 1.75% notes due 2032 and shares at $17.00 ahead of its first approval. It used part of the money to pay off about $55.1 million of term debt.
VRDNThe private placement closed alongside Odyssey's initial public offering. The Share Purchase Agreement is dated May 7, 2026 and names five placement agents.
ODTXArriVent BioPharma, Inc. filed a prospectus supplement on May 11, 2026 under its existing sales agreement with Jefferies LLC. The last reported sale price was $29.50 per share on May 8, 2026.
AVBPThe prospectus registers resale shares only, so the company gets no proceeds from those sales. It expects Nasdaq trading on or about May 21, 2026, and its own financials carry going-concern doubt.
CNXUArtiva Biotherapeutics agreed to sell 23,871,526 shares at $11.52 each, plus pre-funded warrants for 2,170,138 shares. The company's last reported sale price was $12.52 on May 7, 2026.
ARTVNektar will sell up to $150 million of stock through Guggenheim Securities and H.C. Wainwright at a 3.0% commission. The company used $208.5 million in operations in 2025, and its Phase 3 spending is set to rise.
NKTRFirst-quarter cash was $451.5 million before the April offering. Celldex then expected phase 3 hives data in the fourth quarter of 2026.
CLDXExisting holders agreed to exercise warrants at $0.48 a share in exchange for new Class H warrants, with gross proceeds of approximately $4.20 million if all existing warrants are exercised.
AIMLeerink Partners LLC and Cantor Fitzgerald & Co. are the sales agents. About $58.5 million of ADSs had already been sold, leaving $341,478,784 of capacity after the supplement.
GPCRFirst-quarter U.S. BRIUMVI sales rose 63% to $194.8 million. A $750 million Blue Owl loan in March funds growth and repurchases.
TGTXInflaRx N.V. sold 75,000,000 ordinary shares in an underwritten offering led by Guggenheim Securities. The offering closed on May 7, 2026.
IFRXThe new program runs through Dec. 31, 2027. First-quarter net product revenue was $555.0 million and 2026 guidance was left unchanged.
EXELCNS Pharmaceuticals priced a private placement of common stock at $2.30 per share and pre-funded warrants at $2.299, for approximately $22.5 million gross. Most of the shares are pre-funded warrants for 9,143,479 shares. Closing is expected May 5, 2026. A director resigned and a new one was named.
CNSPVeradermics closed an underwritten sale of 3,843,790 shares at $100.00 and a $30.0 million private placement of pre-funded warrants on May 1. Its pivotal hair-loss trials are still running against $70.0 million of annual losses.
MANECue Biopharma agreed to pay a $15.0 million upfront for rights to Ascendant-221, an anti-IgE antibody still in a Phase 2 study run by the licensor's affiliate, and to issue pre-funded warrants for up to 551,724 shares. Milestones could reach $676.5 million, and the company's own release cites a current going concern determination.
CUEThe company priced 16,750,000 shares at $18.00 each, with delivery expected on or about May 4, 2026. It had net losses of $63.9 million in 2025 and no approved products.
COAGRegentis Biomaterials Ltd. filed a Form F-1 on May 1, 2026 for a firm commitment offering through ThinkEquity. The $3.00 price is the April 28, 2026 NYSE American close.
RGNTThe offering totals $254,880,000 before fees, and Seaport expects net proceeds of about $233.9 million. Entities affiliated with General Atlantic, a holder of more than 5% of the stock, have indicated interest in up to $50 million of shares, which is not binding.
SPTXThe offering totals $300,000,006 before fees. The shares have been approved for listing on the Nasdaq Global Select Market as AVLN.
AVLNValneva agreed on April 29, 2026 to sell 15,893,817 new shares, each with a warrant, for €37 million. The warrants could add about €47 million if every one is exercised, at €2.96 each.
VLAInMed agreed to amend the exercise prices on preferred investment options held by Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC to $0.80 per share.
INMIntellia filed to sell $150 million of common stock on April 27, 2026 and priced 16,744,187 shares at $10.75 on April 28. Its preliminary cash at March 31 was $517.2 million, and its risk factors say the FDA has lifted a clinical hold on the nex-z Phase 3 trials.
NTLACitius Pharmaceuticals sold 4,730,457 shares at $0.985 and pre-funded warrants for 345,686 shares, and it will issue warrants at $0.86 a share. The prospectus supplement also reports substantial doubt about its ability to continue as a going concern.
CTXRCTORThe company will receive no proceeds from the resale. It also has agreements to sell 937,500 shares of Series C Preferred Stock for gross proceeds of $7,500,000, and its audited 2025 statements carry a going concern warning.
LABTAmneal will pay $375 million in cash and issue 28,942,108 shares to buy Kashiv BioSciences, and some sellers are affiliates of the Amneal Group. Up to $350 million more depends on US regulatory milestones for Kashiv products.
AMRXAltimmune sold 64,250,000 shares at $3.00 with a warrant for each share, against a last reported sale price of $3.47 on April 22, 2026.
ALTMaze Therapeutics, Inc. is selling 5,540,000 shares at $23.50 each and pre-funded warrants for 850,000 shares. Leerink Partners LLC is sole underwriter, and dilution to new investors is $14.40 per share.
MAZEThe agreements dated April 21, 2026 cover 17,500,000 shares at $0.04 per share, and the offering closed the same day. The filing names no underwriter or placement agent.
HEPASILV Fund Ltd. replaces Point72 Associates, LLC for 531,670 shares. The resale prospectus still covers up to 39,425,806 shares, against 49,542,691 outstanding on February 28, 2026.
ORKALeerink Partners, Guggenheim Securities and Oppenheimer & Co. are joint book-running managers, with Jones and Craig-Hallum as co-managers.
SPRBDaré issued 20,000 Investor Units at $5.00 each, with one Series A Convertible Preferred share and two warrants per unit. The offering is for up to 4,854,000 units, and the company's auditor has raised going concern doubt.
DAREKailera Therapeutics (Nasdaq: KLRA) sold 44,921,875 shares in its initial public offering, including the underwriters' full option. A restated charter set up a classified board and exclusive forum rules.
KLRAAN2 Therapeutics filed an $80,000,000 prospectus supplement dated April 20, 2026 for sales through Jefferies LLC, which will be deemed an underwriter, earns up to 3.0% of gross proceeds and is under no obligation to sell any set amount.
ANTXAlamar priced 11,250,000 shares at $17.00 each, and the underwriters later exercised their option in full, bringing gross proceeds to about $219.9 million.
ALMRThe offering totals $625,000,000 before fees. Existing stockholders have indicated interest in buying up to approximately $225 million of shares.
KLRAOdyssey Therapeutics, Inc. filed a Form S-1 on April 17, 2026. The cover leaves the share count and price range blank.
ODTXThe company agreed to sell 2,222,223 shares at $2.25 per share with warrants, for about $5 million upfront, with H.C. Wainwright & Co. as placement agent.
ENVBAcurx agreed to sell 816,068 shares at $3.03 and pre-funded warrants for 9,017 shares, plus Series H warrants at $2.78 in a concurrent private placement. H.C. Wainwright & Co., LLC is the placement agent, and the 10-K says existing resources will not fund operations for at least 12 months.
ACXPAchieve Life Sciences agreed on April 15, 2026 to sell shares, pre-funded warrants and warrants for anticipated gross proceeds of about $180.0 million, with up to $173.8 million more if the warrants are exercised. Chief Executive Richard Stewart steps down on April 18, 2026.
ACHVTrevi sold 11,600,000 shares at $13.00 each, about $150 million, below the $14.54 last sale on April 16, 2026. Its two pivotal Phase 3 trials for Haduvio are not due to report until the second half of 2027 and the first half of 2028.
TRVITelix raised its convertible notes offering from US$550 million to US$600 million and will use most of the money to buy back its 2029 convertible bonds. The reference price for the conversion terms was set at an 8.0 per cent discount to the closing share price.
TLXThe warrants cover up to 5,770,335 shares at $5.199 per warrant share, with closing expected on or about April 14, 2026. ImageneBio plans to use the proceeds for its IMG-007 programs.
IMAThe amendment names Maxim Group LLC as exclusive sales agent and removes the limit on the amount of shares that can be sold under the agreement.
AIMHemab Therapeutics Holdings, Inc. filed a Form S-1 on April 10, 2026, with the share count and price range left blank. Its lead drug has had serious thrombosis events, and the company reported a net loss of $63.9 million for 2025.
COAGSeaport Therapeutics filed its Form S-1 on April 10, 2026 with the share count and price range still blank. The filing shows a 2025 net loss of $74,881 thousand and a stockholders' deficit of $92,545 thousand.
SPTXAN2 Therapeutics set up an $80 million at-the-market sales program with Jefferies LLC on April 9, 2026 and ended an earlier agreement with TD Securities, against a 2025 net loss of $35.2 million and cash used in operations of $29.8 million.
ANTXEnsysce Biosciences sold 2,000 shares of Series B preferred stock for $2 million on April 6, 2026, to 3i, LP. The deal comes with warrants for up to 8,727,273 common shares, all at $0.55, and the stated value of the preferred stock was raised from $1,100 to $1,200 a share.
ENSCAvalyn Pharma Inc. filed a Form S-1 on April 8, 2026. The cover leaves the share count and price range blank.
AVLNPhio set up an at-the-market program that lets it sell up to $6,360,000 of common stock through H.C. Wainwright & Co., LLC, with a 3.0% commission. The size is capped because its public float is only $19,080,217, and its auditors have raised a going concern doubt.
PHIOA note exchange and a $500,000 preferred sale both closed April 7, 2026. Univest Securities, LLC was the placement agent for the offering.
AQBKiora Pharmaceuticals, Inc. closed the deal with Perceptive Advisors and ADAR1 Capital Management on April 6, 2026, with $5.0 million in upfront funding. Up to $19 million more could come if milestone-based warrants are exercised.
KPRXEntera Bio sold 7,827,789 units to funds affiliated with BVF Partners LP at $1.2775 a unit, with the closing on April 2, 2026. The 8-K names no placement agent or bank, and the company's 10-K says its cash covers operations only through the middle of the third quarter of 2026.
ENTXThe Equity Distribution Agreement is dated March 23, 2026. Piper Sandler's commission is 3.0% of the gross sales price per share, and the prospectus says the $4.07 share price is below net tangible book value per share.
AARDAdagene Inc. priced 18,666,000 American depositary shares at $3.75 for about $70.0 million gross, below the $4.61 last sale price on April 1. Leerink Partners LLC and LifeSci Capital LLC are joint book-running managers, and cash stood at $74.5 million at the end of 2025.
ADAGCardiol says $31 million of gross proceeds from an October 2025 private placement and a January 2026 bought deal funds it through its Phase III pericarditis trial. The release names no underwriter or placement agent.
CRDLOnKure Therapeutics, Inc. is selling 26,713,636 shares and pre-funded warrants for 9,430,959 shares to institutional accredited investors. AI Biotechnology LLC is lead investor and gets a board nominee right.
OKURThe company sold 1,536,885 shares at $1.952 per share, with the sale closing on March 27, 2026. It also signed an agreement with Iterative Health to help enroll patients in its planned Phase 2 ulcerative colitis study.
PALIAlamar Biosciences filed an S-1 on March 27, 2026, reporting a 2025 net loss of $29.8 million on revenue of $74.2 million. The cover leaves the share count and price range blank.
ALMRAnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs.
ANABTRAXKailera Therapeutics, Inc. filed a Form S-1 on March 27, 2026. The cover leaves the share count and price range blank.
KLRASatellos Bioscience Inc closed the equity offering on February 9, 2026 and began trading on the Nasdaq Global Market under the ticker MSLE. Cash was $27.7 million at year end.
MSCLThe 2025 financing closed in two parts before the IPO. Holders tied to board members were among the buyers, the proxy shows.
MPLTMeiraGTx (Nasdaq: MGTX) moved the maturity of its Perceptive notes from August 2, 2026 to May 2, 2027. It will redeem $25,000,000 by June 30, 2026, and Perceptive's warrants are repriced to $8.00.
MGTXUpstream Bio signed a sales agreement with Leerink Partners LLC on March 26, 2026 that lets it sell up to $150,000,000 of common stock on the Nasdaq market. Leerink may earn a commission of up to 3.0% of gross proceeds, and cash used in operations rose to $133.3 million in 2025.
UPBNkarta set up a $100 million at-the-market program with Stifel on March 25, 2026, with commissions of up to 3%. Its 2025 net loss was $104.1 million, and its operating cash use was $88.7 million.
NKTXRenovoRx (Nasdaq: RNXT) sold 8,438,790 shares, pre-funded warrants and revenue milestone warrants to 15 investors, five of them insiders. The deal closed March 20, 2026.
RNXTAardvark Therapeutics, Inc. signed an equity distribution agreement with Piper Sandler & Co. on March 23, 2026 and filed a Form S-3 shelf registration the same day. The company paused its main Phase 3 trial in February 2026 after cardiac observations in a healthy volunteer study.
AARDThe board lifted the program from $10 million. The company had repurchased approximately $2.6 million of stock through March 17, 2026.
NAGENuCana's cash rose to £24.3 million after two 2025 raises, but its 2025 net loss was £29.4 million and net cash used in operating activities was £7,467 thousand. The melanoma data for NUC-7738 come from an expansion study the release does not size.
NCNAStoke's shelf includes a $150,000,000 at-the-market program with Cantor Fitzgerald, which can be paid up to 3.0% of gross proceeds in commissions. The stock's last reported sale price was $33.96 on March 16, 2026.
STOKTalphera (Nasdaq: TLPH) sold 639,931 shares at $0.586 and pre-funded warrants for up to 6,399,316 shares on March 13, 2026, to purchasers who did not join the earlier Optional Closing.
TLPHAcumen Pharmaceuticals, Inc. entered into a securities purchase agreement with institutional and accredited investors. RA Capital Management, an existing investor, led the deal, and the release names no placement agent.
ABOSAmphastar's board raised its buyback by $50 million on March 12, 2026, to offset dilution from equity compensation, while 2025 net income fell to $98.1 million and cash from operations dropped.
AMPHCytomX priced 45,990,567 shares and pre-funded warrants for 1,179,245 more at $5.300 a share, below the $5.45 last reported sale price on March 17, 2026. Its lead clinical data are interim, and the prospectus gives no patient count or response rate.
CTMXThe filing assumes a $5.50 unit price, which would bring net proceeds of about $17.98 million. The financial statements carry a going-concern paragraph, and the accumulated deficit was $38,027,000 at September 30, 2025.
INNOCorvus had sold no shares under its $100,000,000 Jefferies program and had suspended it in January. The amendment doubles the ceiling to $200,000,000, with Jefferies paid up to 3.0% of gross proceeds.
CRVSThe sale came a day after phase 3 X-TOLE2 results. Xenon ended March with $1.34 billion in cash and says it funds operations into 2029.
XENEThe company is selling 8,245,611 shares and pre-funded warrants for up to 5,789,493 shares to institutional investors. Leerink Partners is the exclusive placement agent, and closing is expected March 10, 2026.
ANTXSepterna can sell up to $150,000,000 of stock through BofA Securities, at a fee of up to 3.0%. Its 2025 net loss was $48.9 million, yet cash from operations was positive at $110.2 million, a swing the shelf filing does not explain.
SEPNRelmada agreed to sell 29,474,569 shares and pre-funded warrants for up to 4,210,527 shares to institutional and accredited investors. It announced 12-month Phase 2 data for NDV-01 the same day, where the 12-month response rate rests on 25 patients.
RLMDDianthus priced 7,313,582 shares and pre-funded warrants for 402,468 shares at $81.00, for $624,999,648 in total, after launching a $400,000,000 offering. Its 2025 net loss was $162.3 million, and the supplement names no counsel.
DNTHThe company signed a sales agreement with Leerink Partners LLC on March 9, 2026. It ended an earlier agreement with Jefferies LLC under which no shares were sold.
ENGNKorro Bio, Inc. is selling 4,501,928 shares at $11.11 and pre-funded warrants for 3,148,836 shares. The company expects the money to extend cash runway into the second half of 2028.
KRROEupraxia Pharmaceuticals Inc. sold 7,607,145 common shares at US$7.00 each, plus pre-funded warrants for 1,428,571 shares. The material change date is February 20, 2026.
EPRXNurix raised its Piper Sandler at-the-market program to $413.65 million, of which $113.65 million has already been sold. Its fiscal 2025 net loss was $264.5 million and cash used in operations was $249.5 million.
NRIXSolid Biosciences agreed to sell 14,973,257 shares at $5.61 and pre-funded warrants for 27,807,482 shares, for about $240.0 million gross. Its year-end 2025 cash figure is a preliminary, unaudited estimate, and the company says the deal extends runway into the first half of 2028.
SLDBContineum can now sell up to $100 million of Class A stock through Leerink Partners LLC, and its dilution example shows $7.18 a share lost at a $15.34 price. The company has also deferred two programs until it obtains funding.
CTNMEvaxion says its cash can fund operations into the second half of 2027, after a $7.5 million option exercise fee and a debt conversion with the European Investment Bank. The release reports a cash burn of about $14 million for 2026 and names no bank or agent for its amended at-the-market facility.
EVAXMediWound ended 2025 with $53.6 million in cash, cash equivalents and deposits after a $30.0 million registered direct offering. Its net loss narrowed to $23.9 million mainly because of warrant revaluation, while revenue fell to $17.0 million.
MDWDRegen Biopharma issued 77,849,847 common shares between February 4 and February 27, 2026 to settle convertible debt and fees. The company had 212,318,424 shares outstanding on March 3, 2026, and its pipeline has not yet entered a clinical trial.
RGBPChina Pharma's subsidiary Helpson agreed on February 26, 2026 to buy a sublingual tablet patent for $6.93 million, paid in 12,600,000 unregistered shares at $0.55 each. The company has a going-concern warning in its latest annual report.
CPHIGyre Therapeutics agreed to buy privately held Cullgen in an all-stock deal valued at about $300 million, issuing common stock and Series B convertible preferred. Until stockholders approve the conversion, Gyre may not issue more than 19.99% of its stock, and Cullgen's lead drug has completed only a Phase 1 trial.
GYREZymeworks sold 30% of its future Ziihera royalties to a subsidiary that borrowed $250 million from Royalty Pharma. The loan costs about $481 million by its 2042 maturity, and it is secured by the subsidiary's assets.
ZYMEBelite Bio says its $402 million offering was completed with the overallotment option fully exercised. The same release reports a 2025 net loss of $77.6 million, up from $36.1 million, and cash of $352.9 million at year-end.
BLTEThe sales agreement pays TD Securities (USA) LLC up to 3.0% of gross proceeds. Geron's stock last sold at $1.65 on February 26, 2026, and the company's 2025 net loss was $83.5 million.
GERNSionna Therapeutics signed a sales agreement with Leerink Partners LLC on March 2, 2026 for up to $250,000,000 of common stock sold at the market. Leerink's commission is up to 3.0% of the gross sales price per share.
SIONThe offering totals $400,000,000 before costs, with net proceeds estimated at $368.8 million. The prospectus keeps the going-concern warning and says no pivotal trial has finished.
GENBLipocine Inc. filed a prospectus supplement on February 26, 2026 under its sales agreement with A.G.P./Alliance Global Partners. It had sold $10,615,576 of stock under the earlier registration.
LPCNLargest stockholder Deerfield and some directors indicated interest in buying. The priced offering is 20,000,000 shares at $5.00, or $94,000,000 to the company before expenses.
LRMRBicara priced 7,175,000 shares at $16.00 and pre-funded warrants for 2,200,000 more, with underwriting discounts of $9,000,000 on a total of $149,999,780.
BCAXCyprium, a majority-owned Fortress Biotech subsidiary, agreed on February 22, 2026 to sell a priority review voucher for $205 million in cash at closing. Fortress also amended its Oaktree credit agreement, with about $29.5 million outstanding.
FBIOThe February 18, 2026 amendment sets the change-of-control payment to HCR at $150 million or $200 million and revises a buyout option. HCR received warrants at $3.8130 per share.
ADCTVir Biotechnology agreed to co-develop VIR-5500 with Astellas for $335 million in upfront and near-term payments, plus up to $1.37 billion in later milestones. The drug is still in Phase 1, and the deal closes only after Hart-Scott-Rodino clearance.
VIROric Pharmaceuticals, Inc. has sold 13,478,432 shares under the program for gross proceeds of approximately $139.7 million. The new supplement replaces the one from March 2024.
ORICVir Biotechnology will receive $335 million in upfront and near-term payments from Astellas for VIR-5500, a prostate cancer T-cell engager still in Phase 1. Its February 25 prospectus supplement priced a $150,000,002 stock offering at $8.50 per share.
VIRPurchasers paid $3.39 per share for 7,374,632 non-voting convertible preferred shares. Conversion into common stock depends on stockholder approval at the 2026 annual meeting. Preliminary cash was $45 million at year end.
IRDGeoVax sold 402,000 shares and pre-funded warrants for up to 30,902 shares, plus Series A-1 and A-2 warrants in a concurrent private placement. H.C. Wainwright & Co., LLC was placement agent.
GOVXEvommune's $125 million private placement was followed by a failed atopic dermatitis trial; the company says its 2026 raise brought net proceeds of $117.2 million.
EVMNREGENXBIO filed a prospectus supplement for up to $150 million of at-the-market stock sales through Leerink Partners. The filing warns of substantial doubt about its ability to continue as a going concern.
RGNXSpyGlass Pharma closed a $172.5 million IPO with Jefferies, Leerink Partners, Citigroup and Stifel running the book. The money is meant to carry a glaucoma implant through two Phase 3 trials.
SGPAgomAb priced 12,500,000 ADSs at $16.00 for $200,000,000 and expects about $181 million in net proceeds. Its lead drug has shown only safety results in a Phase 2a Crohn's trial, and the prospectus reports an accumulated loss of €164.3 million.
AGMBVeradermics closed its initial public offering of 15,077,647 shares at $17.00 a share on February 5, 2026. The underwriters later exercised in full their option on 2,261,647 more shares.
MANELB Pharmaceuticals agreed to sell 3,306,571 shares and pre-funded warrants for up to 1,417,107 shares to institutional investors. It plans to use the proceeds for a Phase 2 trial of LB-102 in major depressive disorder and for general corporate purposes.
LBRXThe offering totals $381,196,800. The stock is approved to list on Nasdaq under EIKN, and proceeds to the company are $354,513,024 before expenses.
EIKNThe S-1 leaves the share count and price range blank. Management and the auditor say cash will not last twelve months, which raises going-concern doubt.
GENBPerspective Therapeutics priced 39,576,088 shares at $3.79 each, plus pre-funded warrants for 6,598,046 shares, for gross proceeds of about $175 million. Piper Sandler & Co. is one of five joint book-running managers, and Hogan Lovells US LLP is counsel to the company.
CATXALX Oncology priced 76,979,112 shares and pre-funded warrants for 18,574,120 more, at $1.57 a share, after a year of failed or dropped combination trials and a narrower focus on its CD47 drug evorpacept.
ALXOThe senior notes due 2034 priced at par and will sit in escrow until the deal closes. BioMarin also completed syndication of a $2 billion term loan B.
BMRNAprea expects gross proceeds of approximately $5.6 million from selling 6,288,857 shares, or pre-funded warrants, with common warrants for the same number of shares at $0.765. Maxim Group LLC is placement agent for a 7% fee. Closing is expected January 30, 2026.
APREAltimmune is selling 12,397,920 shares at $4.40 each, plus pre-funded warrants for 4,647,534 shares, to one investor, with Titan Partners Group LLC as sole placement agent.
ALTVivani will sell 1,689,200 shares in a registered direct offering and 1,351,351 shares in a private placement at $1.48 each. ThinkEquity is sole placement agent for the registered part, and the company used $20,786 thousand in operations in 2024 against $19,690 thousand of year-end cash.
VANIRA Capital exchanged 4,850,000 shares and Biotechnology Value Fund exchanged 1,750,000 shares. The company had 51,007,874 shares outstanding as of January 23, 2026.
FDMTLarimar agreed with Blue Owl Healthcare Opportunities IV Public Investments LP to swap 2,500,000 common shares for 250,000 Series A convertible preferred shares. Each preferred share converts into 10 common shares, and closing is expected January 23, 2026.
LRMREach share of Series A convertible preferred stock converts into 10 shares of common stock, subject to certain limitations. The exchange was expected to close on January 23, 2026.
LRMRBioAge Labs priced 5.9 million shares with Goldman Sachs, Piper Sandler and Citigroup nine days after new phase 1 data on BGE-102, its brain-penetrant NLRP3 inhibitor.
BIOAAEON Biopharma exchanged its senior secured convertible notes held by Daewoong for new shares, pre-funded warrants and a smaller $1,500,000 note after stockholders approved the deal on January 21, 2026. The swap adds dilution, and the second closing of its private placement is still pending.
AEONAgomAb Therapeutics filed to sell American depositary shares and list them on Nasdaq as AGMB. The price range and share count are blank, and the company has a Phase 2a Crohn's trial whose published results were on safety only.
AGMBTiziana Life Sciences Ltd sold 7,040,000 ordinary shares to senior management and existing shareholders without a placement agent. Each share came with a warrant at $1.50.
TLSABriaCell Therapeutics sold 5.4 million units at $5.59, each with a five-year warrant struck at $6.93. The best-efforts deal closed Jan. 15.
BCTXThe AI-driven antibody company sold shares and pre-funded warrants at $2.35 in a private placement. It says the cash runs into calendar 2028 and that first human trials of IBIO-610 start in early 2027.
IBIOThe Delaware company applied to list on the Nasdaq Global Market. The share count and price range are blank in the preliminary prospectus.
EIKNMonte Rosa Therapeutics priced 12.5 million shares and pre-funded warrants at $24 the day after interim phase 1 data on MRT-8102, an oral molecular glue aimed at heart-disease inflammation.
GLUEGenelux sold 6,666,667 shares at $3.00 through Lucid Capital Markets, raising about $20.0 million gross. The oncolytic virus developer is running a phase 3 trial of Olvi-Vec in platinum-resistant ovarian cancer, and its China partner Newsoara holds the rights there.
GNLXThe radiopharmaceutical developer sold 17.65 million shares on the Nasdaq, the first U.S. biotech IPO of 2026, after raising its offering size.
AKTSLLYBMYMRKAlumis sold 17.65 million shares at $17 after two phase 3 trials of its oral TYK2 inhibitor envudeucitinib met all endpoints. A prospectus had flagged going-concern doubt before the deal.
ALMSThe emavusertib developer sold preferred stock with three warrant series at $0.75, one of them timed to an enrollment goal in its leukemia trial.
CRISPhathom priced 6,875,000 shares at $16.00 plus pre-funded warrants for 1,250,078 shares, for a public offering of $129,999,998. Its cash fell from $297.3 million at the end of 2024 to a preliminary $130 million at the end of 2025, and the company expects operating profit only in the second half of 2026, excluding stock-based compensation.
PHATPraxis Precision Medicines sold 2.2 million shares to fund launch plans for two Breakthrough-designated drugs. Net proceeds later came to $621.2 million.
PRAXThe December 31, 2025 warrant went to Paramora Holding LLC at $23.01 per share under an October 7, 2025 option agreement with Paragon Therapeutics. The board named Sherwin Sattarzadeh Chief Operating Officer.
DMRAThe registered direct offering is expected to bring in about $234,000 before expenses. IGC Pharma says it will use the money for working capital and general corporate purposes.
IGCZura Bio will issue 8,657,402 Class A shares to Athanor Capital and pay it a $7,325,000 upfront fee within 30 days, ending its Stone Peach and BAFFX17 arrangements. An internal audit subcommittee review found no issue that affected previously filed financial statements, and the Athanor deal adds a $25,000,000 milestone payment.
ZURAThe exchange closed on December 30, 2025. The warrant has an initial exercise price of $0.001 per share.
ELDNThe at-the-market sales agreement names Cantor Fitzgerald, Wells Fargo Securities and William Blair. As of December 22, 2025, the company had sold 1,179,201 shares under it for about $12 million.
ARCTHolders would receive all resale proceeds. Mesoblast would receive US$16.25 per ADS if the warrants are exercised.
MSBThe company amended its sales agreement with Jefferies and filed a new prospectus supplement. It also confirmed a higher authorized share count.
IBRXBiodexa priced 157,000 units and 2,891,781 pre-funded units at $3.28 each, with two Series L warrants per unit. The last reported sale price of the ADSs was $6.50 on December 16, 2025.
BDRXLarimar Therapeutics agreed to swap 2,500,000 common shares held by a Blue Owl fund for 250,000 Series A convertible preferred shares, each convertible into 10 common shares. The filing calls the preferred "toothless," and the holder can raise its conversion blocker to 19.99%.
LRMRCadrenal will sell 207,374 shares at $10.85 plus unregistered warrants for up to 414,748 shares at $10.60, for expected gross proceeds of about $2.2 million. H.C. Wainwright & Co., LLC is exclusive placement agent.
CVKDLexaria sold 2,661,600 shares at $1.315 in a registered direct offering and placed matching warrants at $1.19, for about $3.5 million gross. H.C. Wainwright & Co., LLC was placement agent. Its annual report says the company has substantial doubt about continuing as a going concern.
LEXXRadiopharm Theranostics filed a $50,000,000 shelf registration on December 16, 2025 and a sales agreement with Leerink Partners the same day. A prospectus supplement filed December 23 set up to $18,900,000 of at-the-market sales.
RADThe 10-K reports GEM bought 1,235,200 shares for about $4.07 million in 2025 under an $85.0 million agreement. The company has since drawn a $7.0 million term loan and flagged going-concern doubt.
TTRXImmunome said on December 15, 2025 that it planned a $400 million stock offering, and priced it the next day at $21.50 a share.
IMNMThe preliminary filing leaves the size and price blank. There is no minimum amount, so the company may sell fewer shares than offered.
TLSAClimb Bio agreed on December 11, 2025 to take back 20,440,000 shares from an entity affiliated with RA Capital in exchange for a pre-funded warrant. After the exchange, RA Capital and its affiliates will hold about 23.0% of the voting power, and the filing describes no cash payment to the company.
CLYMAddex Therapeutics amended its at-the-market agreement with H.C. Wainwright and filed a prospectus supplement for up to $3,300,000 of ADSs. The company reported CHF 2.2 million of cash at September 30, 2025 and says it covers expenses through mid-June 2026.
ADXNThe supplement covers $125,000,000 of a sales agreement that allows up to $200,000,000 in total. TD Securities (USA) LLC can earn up to a 3.0% commission, and the filing gives a November 20, 2025 closing price of $2.38.
CCCCEvaxion says its public float now passes $75.0 million, which lifts a sales cap and allows up to $45.52 million more in ADS sales through JonesTrading. The float figure uses an October share price, and the stock was $6.28 in early December.
EVAXThe $150.0 million offering priced on December 10, 2025 at $13.50 a share and was upsized to $175.0 million. Its lead drug data come from 12 patients in one dose cohort, and the dose comparison rests on six.
FULCWave Life Sciences filed a preliminary prospectus supplement on December 8, 2025 for a $250,000,000 offering. The pricing that followed on December 9 raised the deal to about $350 million at $19.00 per ordinary share.
WVECrescent agreed to sell 13,795,685 ordinary shares at $13.41 for about $185.0 million. Two license deals with Kelun-Biotech require Crescent to pay $80.0 million within 30 days of signing, while Kelun-Biotech pays it $20.0 million in the same period.
CBIOBaxter closed a three-series senior notes offering on December 4, 2025 and used part of the proceeds to repay its term loan. The rest is earmarked for cash tender offers on older notes, so the company is swapping debt rather than shrinking it.
BAXThe 45,472,000 shares are sold to US investors through the company's at-the-market facility, according to a note in the filing. The filing names no lead manager or underwriter.
IMCThe deal has no common warrant coverage but includes prefunded warrants. Kazia expects net proceeds of approximately $46.5 million and says its cash runway would extend into the second half of 2028.
KZIAPolyPid can now sell up to $15,000,000 of ordinary shares through Oppenheimer & Co. Inc., up from $8,250,000, paying a 3.0% commission. Its shares closed at $3.68 on November 25, 2025, and the supplement does not say how much cash the company has.
PYPDVerrica agreed to sell common stock, pre-funded warrants and Series C warrants for about $50 million, and will use $35.0 million to settle its OrbiMed credit agreement. The company says cash will last into mid-2027.
VRCAThe best efforts sale would pair each ADS with a Series L warrant whose exercise price resets after issue. The company says it will likely receive no additional cash when those warrants are exercised.
BDRXThe company sold 1,970,000 shares at $1.68 per share and pre-funded warrants for up to 1,601,429 shares to one investor, and issued Series A and Series B warrants in a concurrent private placement.
NNVCAcumen has sold $12.3 million of stock under its sales agreement so far, which leaves $37.7 million available. BofA Securities, Stifel and BTIG are the sales agents.
ABOSThe new shelf replaces one that expires on November 22, 2025. It carries forward $400,005,680.55 of securities that remain unsold under the earlier registration.
BDTXThe at-the-market supplement lets Cantor Fitzgerald sell up to $50,000,000 of stock for up to 3.0% in commissions. The company's lead drug failed its Phase 3 Alzheimer's study, and its share price closed at $3.11.
FLNAAnnexon priced 25,096,153 shares at $2.60 for about $75 million on November 12, 2025, with pre-funded warrants for up to 3,750,000 more shares, and its two lead programs are still in late-stage trials.
ANNXGuggenheim Securities, LLC is the sole underwriter. The company sells 10,815,000 shares, each with half a warrant, at a combined $6.14. Proceeds are $70,500,087 before expenses, and the as adjusted net tangible book value would be $3.74 a share.
DTILLyell Immunopharma agreed to pay $40 million in cash and issue 1.9 million shares for exclusive rights to LYL273, a CAR T candidate for colorectal cancer that has been tested in 12 patients. The deal also carries more shares, large milestone payments and tiered royalties, and the company says its cash lasts into 2027 once it closes.
LYELEvommune sold 9,375,000 shares at $16.00 in its New York Stock Exchange listing, with a 30-day option on 1,406,250 more. Its most advanced drug's efficacy data come from a small Phase 2 study in a different condition than the one it is pursuing.
EVMNHolders exercised existing warrants, most at a reduced $2.05 per share, in return for new Series A Warrants. Phio expects total gross proceeds of approximately $13.4 million before fees.
PHIO4D Molecular Therapeutics priced an offering of about $100 million in shares and pre-funded warrants at $10.51 each, with Leerink Partners LLC and Evercore Group L.L.C. as joint bookrunners. Preliminary cash of $372.2 million is unaudited, and new buyers face immediate dilution of $1.36 per share.
FDMTPrelude Therapeutics gave Incyte an option on its preclinical JAK2V617F JH2 inhibitor program for a $35 million cash payment, plus a $25 million stock purchase. Exercising the option would cost Incyte $100 million, and the company is pausing a separate SMARCA2 degrader program.
PRLDTaysha filed an automatic shelf on November 4, 2025, with a sales agreement of up to $200,000,000 of common stock. As of November 3, 2025, it had sold $12,000,000 under the earlier agreement, while its third-quarter net loss was $32.7 million.
TSHAJefferies LLC is the sales agent for up to $100,000,000 of common stock. A second Jefferies program, dated January 18, 2023, may still sell up to approximately $80.0 million.
ARDXCytoDyn can sell up to $30 million of common stock to Yorkville Advisors Global over 36 months, at its own discretion and with no warrants attached. The release names no placement agent or counsel, and the annual report says the company will pursue non-dilutive financing in addition to traditional fundraising.
CYDY4D Molecular Therapeutics agreed on October 31, 2025 to license 4D-150 to Otsuka for Asia-Pacific markets in exchange for an $85 million upfront payment. The company keeps leading global Phase 3 work, and Otsuka's expected cost sharing is at least $50 million over three years.
FDMTOperating cash outflows were A$5.34M for the quarter ended 30 September 2025. The company says the placement was led by healthcare-focused funds.
ATHSavara priced 23,809,524 shares at $4.20, below the $4.41 last sale price, and pre-funded warrants for 7,142,857 more. Jefferies, Piper Sandler and Guggenheim Securities are joint book-running managers, and Polsinelli PC is the company's counsel.
SVRAMapLight Therapeutics closed its initial public offering at $17.00 a share, and the underwriters exercised their option for more shares in full. Its lead drug has no Phase 2 results yet.
MPLTGSVivo Capital LLC led the deal, which brings $80 million upfront in Series A preferred stock. The rest comes from two warrant tranches, and the larger one is tied to a Phase 3 roluperidone trial meeting its primary endpoint.
NERVKeros Therapeutics, Inc. offers to buy back its stock for cash, for up to $194.4 million in total. The Schedule TO was filed October 20, 2025.
KROSLexeo agrees to sell 15,625,000 shares for expected gross proceeds of approximately $125 million. A concurrent private placement of pre-funded warrants is expected to bring approximately $10 million.
LXEOMedicus Pharma (Nasdaq: MDCX) sold shares in eight transactions between September 8 and October 16, 2025 for approximate aggregate consideration of $2,526,364. It used part to prepay a Yorkville debenture.
MDCXEach share or pre-funded warrant comes with two warrant classes, each covering 50,608,500 shares at $2.22. C4 says the net proceeds would extend its cash runway to the end of 2028, and the larger $341.7 million figure assumes every warrant is exercised for cash.
CCCCQuoin sold ADSs and pre-funded warrants with four series of warrants whose cash exercise depends on FDA and trial events that the filings do not report as having happened. Maxim Group LLC was the exclusive placement agent, and director Dennis Langer took part.
QNRXHolders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026.
CLRBHolders exercised warrants for 1,048,094 shares at $5.25 and received new warrants at $6.00. Cellectar says cash should last into the third quarter of 2026.
CLRBCanaccord Genuity is sole bookrunner. Xenetic plans to use net proceeds for working capital and general corporate purposes.
XBIOThe note bears interest at 3.81% a year and is tied to the closing of an asset and stock purchase deal the companies signed on June 3, 2025.
AGENINKTThe shares were issued between October 1, 2025 and October 8, 2025. The company had 3,801,604 common shares outstanding as of October 8, 2025.
ALZNThe twelve-month program starts October 15, 2025. The company says it represents approximately 5% of the 46,154,188 common shares outstanding.
HYFTThe deals combine new loans and notes, payment deferrals, debt-for-equity exchanges and a private placement of about $8.75 million. Karyopharm expects about $36 million of gross proceeds and a cash runway into the second quarter of 2026.
KPTIThe sale to a single investor was made under the company's at-the-market agreement with TD Securities (USA) LLC. LENZ reported the 1,748,634 shares sold at $45.75 in an 8-K filed October 8, 2025.
LENZInstitutional investors are buying 502,181 shares at $68.00 and pre-funded warrants for 233,144 more, for expected gross proceeds of about $50.0 million. The 8-K contains no clinical data for tralesinidase alfa, the program Spruce plans to file in the first quarter of 2026.
SPRBZenas gains global rights to the BTK inhibitor outside oncology plus two early autoimmune drugs. It also registered an at-the-market program for up to $200,000,000 of stock with Jefferies.
ZBIOHumacyte is selling 28,436,018 shares, with warrants for the same number of shares, at $2.11 per share and warrant. The release does not say how the proceeds will be used.
HUMAJade Biosciences agreed to a PIPE financing of about $135 million at $9.14 per share, with Jefferies, TD Cowen, Stifel and Wedbush named as placement agents, and says its cash will fund operations into the first half of 2028.
JBIOBiomea Fusion is issuing 11,195,121 shares and 1,000,000 pre-funded warrants under an October 6, 2025 prospectus supplement, for $24,999,898 before discounts. Jefferies is book-running manager and H.C. Wainwright & Co., LLC is lead manager.
BMEAUnder a September 14, 2025 inducement agreement, a holder exercised 600,000 series H options and received 600,000 series J options. A separate exercise of 374,167 options produced gross proceeds of approximately $896,000.
MBOTOvid Therapeutics agreed to a private placement of convertible preferred stock and warrants with initial gross proceeds of about $80.8 million and up to $175.1 million in total. The preferred cannot convert until stockholders approve more shares, and the same day the company reported Phase 1 data from 68 healthy volunteers, with the CEO among the investors.
OVIDInstitutional investors bought 7,813 shares of Series E convertible preferred stock and warrants for 2,025,223 common shares. The preferred converts at $3.8576.
ONCOJaguar agreed to sell 161,583 shares and 479,442 pre-funded warrants at $1.56 to Brown Stone Capital Limited. Two days later it issued 286,532 shares to cut a royalty balance by $600,000.
JAGXEdesa and the Government of Canada amended a contribution agreement worth up to CAD $23 million ($17 million USD) in partially repayable funding. Repayment would begin only if the company earns gross revenue.
EDSAAlpha Cognition priced 4,651,516 common shares and pre-funded warrants for 948,484 shares at $6.25 and $6.249, for a total of $34,999,052 before fees. Titan Partners Group is the sole bookrunner, and the company says the money will fund a sales push for ZUNVEYL.
ACOGR.F. Lafferty & Co., Inc. is the sole book-running manager. The filing also cuts the company's at-the-market program to $0 after it sold all the remaining stock under it.
ARTLThe preliminary filing left price and share count blank. The final prospectus supplement, dated September 30, 2025, priced 6,500,000 shares at $10.00, with $61,100,000 going to the company before expenses.
ENTAANI mandatorily converted the last 20,000 preferred shares into 482,320 common shares on September 26, 2025. The filing reports no cash proceeds, and no preferred shares remain outstanding.
ANIPFractyl is selling 60,000,000 shares through BofA Securities, Evercore ISI and Ladenburg Thalmann, after a $1.05 raise in August. The prospectus supplement carries going-concern language.
GUTSThe former TNF Pharmaceuticals began trading on Nasdaq as QCLS on September 26, 2025, under a new name tied to a licensed laser computing technology. The filing does not state how much the September private placement raised.
QCLSBetween September 17 and September 25, 2025, 696 shares of Series B Convertible Preferred Stock converted into common stock. Alzamend had 3,439,861 common shares outstanding as of September 25, 2025.
ALZNCuranex paid $408,537.32 on two notes held by its secretary, Dian Ying Jing, the wife of its chief executive. The payments came on September 23 and 24, 2025, well before the notes matured in 2027.
CURXImmuneering is selling 18,959,914 shares at $9.23 and expects about $164.1 million in net proceeds, plus about $23.3 million from a Sanofi unit. The company's 2024 audit report carried a going-concern paragraph.
IMRXPepGen priced 31,250,000 shares at $3.200 for gross proceeds of $100,000,000, a price above the $2.66 close the filings report for September 24, 2025. The company says the proceeds plus its existing cash will not be enough to finish development of any product candidate.
PEPGAllarity agreed to sell 1,562,500 shares at $1.60 each, or pre-funded warrants, to one investor, closing September 23, 2025. The investor may buy $7.5 million more: within 90 days per the 8-K, 60 days per the purchase agreement.
ALLRThe buyer gets 1,562,500 shares or pre-funded warrants at $1.60 and can add $7.5 million more within 90 days, at a price set by Nasdaq's minimum-price rule.
ALLRMBX Biosciences filed an S-1 on September 22, 2025 for 10,000,000 shares. The deal priced on September 24 at $18.00 for 11,108,055 shares and closed on September 26 with net proceeds of about $187.5 million.
MBXThe company is selling 10,933,405 shares at $15.00 and pre-funded warrants for 1,066,666 more. Closing was expected on or about September 19, 2025.
ORKAEquillium's public float of about $93.7 million lifts it above Form S-3 sales limits. The company had sold $0.96 million of stock under the program so far, against the $21,950,000 covered by the earlier prospectus.
EQIGC Pharma, Inc. set the amount under a $60,000,000 at-the-market sales agreement with A.G.P./Alliance Global Partners. The cap follows a rule that limits small companies to one-third of their public float.
IGCThe size is capped by SEC limits for companies with a public float under $75,000,000. Longeveron's stock last sold at $0.77 on September 18, 2025.
LGVNThe offering covers 5,555,560 shares or equivalents with matching five-year warrants. Soligenix also cut the exercise price on 1,162,064 older warrants to $1.35.
SNGXJasper priced 11,670,707 shares and 675,000 pre-funded warrants, each with a common warrant, at $2.43, for about $30 million before costs. The prospectus also discloses an unresolved trial investigation and a going concern warning.
JSPRThe September 16 registration covered up to 2,800,000 shares at an assumed $2.27. On September 18 the final prospectus sold 4,800,000 shares with warrants at $1.25, for $6,000,000.
BCDAA second closing should add about $4 million. New series J options could bring about $63 million more if fully exercised.
MBOTHolders of 13,065,000 Class H warrants agreed to exercise at $2.20 per share and receive 13,065,000 new Class I warrants in a private placement. Roth Capital Partners advised.
REVBRevelation Biosciences said on September 11, 2025 that holders will exercise warrants for up to 4,355,000 shares at $2.20 each, about $9.6 million in gross proceeds. In return they receive new Class I warrants for up to 13,065,000 shares, which cannot be exercised until stockholders approve them.
REVBThe company agreed to sell 2,764,710 shares at $1.70 each, with warrants for up to 5,529,420 shares at $1.50 that could add approximately $8.3 million if fully exercised for cash. H.C. Wainwright & Co. is the placement agent.
COCPDominari Securities bought 562,500 more shares at the $4.00 IPO price. Total gross proceeds from the offering reached $17,250,000.
CURXThe offering totals $285,000,000, and the shares are approved for listing on Nasdaq under LBRX. Proceeds to the company are $265,050,000 before expenses, and the company's lead drug has a Phase 3 trial still ahead.
LBRXSilexion priced a $6.0 million public offering at $4.00 per share and warrants, with H.C. Wainwright as exclusive placement agent. Its prospectus says cash was $3.5 million at June 30, 2025 and carries a going-concern warning.
SLXNFour investors who could defer their purchases until December 31, 2025 agreed to buy now. In return, TuHURA extended warrants on 1.5 million shares to December 31, 2030.
HURASELLAS says an institutional investor will exercise January 2025 warrants for 19,685,040 shares, bringing about $23.6 million gross. The investor gets new unregistered warrants for the same number of shares at $1.88, so the dilution continues.
SLSAnixa Biosciences filed a $200,000,000 replacement shelf on September 10, 2025, with a $100,000,000 sales program through Cantor Fitzgerald & Co., because its current shelf expires on September 19, 2025 and its clinical programs are still in early trials.
ANIXLeerink Partners is lead placement agent for the $50 million upfront, with Piper Sandler & Co., Cantor Fitzgerald and Wedbush & Co. as co-placement agents. The second $50 million depends on milestones, including clearance to start a trial of CMP-SYNGAP-01.
CAMPShares sold at $0.55 each. Investors other than CorMedix agreed to buy about $12 million more if the NEPHRO CRRT study meets its primary endpoint and the stock clears a price test.
TLPHActuate Therapeutics priced 2,142,858 shares at $7.00 for $15,000,006 in gross proceeds, below the $8.24 last sale price. Lucid Capital Markets is the sole underwriter, and the prospectus says the company's current liabilities exceeded its assets at June 30, 2025.
ACTURein received net proceeds of $0.95 million from the $1.0 million second advance on September 8, 2025. Yorkville buys each advance at 95% of face value, charges 8% interest and can require repayment in stock.
RNTXThe $8.8 million combines an August registered direct offering with at-the-market sales since July 1, 2025. The company says none of it carried warrants, repricing or variable-rate terms, but the filing gives no share count, price or investor names.
NRXPRapport priced 9,615,385 shares at $26.00 the day after reporting Phase 2a epilepsy data for RAP-219, with net proceeds of about $234.7 million. The data came from 30 treated patients and were tested against fixed null rates, not a placebo group.
RAPPDBV Technologies set up a $150 million at-the-market program for American Depositary Shares, sold through Citizens JMP Securities, LLC for a 3.0% commission. The prospectus supplement shows $3.86 per ADS of immediate dilution at a $9.18 reference price.
DBVThe British Columbia company plans a reverse share split and has applied to list on the Nasdaq Capital Market. Titan Partners Group is the sole bookrunner.
OPTIBone Biologics says its June offering raised $5 million gross and that it expects cash to fund operations into the second quarter of 2026, while enrollment in its pilot study is slower than planned.
BBLGCyclacel Pharmaceuticals, now Bio Green Med Solution, agreed to exchange Series C warrants for 559,395 new common shares. The 8-K gives no exercise price and describes no cash payment.
BGMSPrivate investors exercised warrants for 778,041 shares and public holders for 47,076 shares. Employee options added $44,206.
NTRBZenas BioPharma sold Royalty Pharma a share of future obexelimab revenue for up to $300 million. It received $75 million at closing, and the other three $75 million payments depend on a Phase 3 milestone and two FDA approvals. The company says the cash lasts into the first quarter of 2027.
ZBIORPRXFive accredited investors bought restricted stock under subscription agreements signed August 26, 2025 and August 29, 2025. No underwriters were used.
MGRXvTv Therapeutics agreed on August 29, 2025 to sell 5,243,732 units for expected gross proceeds of about $80 million before offering expenses. Each unit carries a warrant exercisable at $22.71, and the placement was expected to close initially on September 3, 2025.
VTVTHolders will exercise warrants for 16,216,216 shares at $0.37. They get new Series F warrants for 64,864,864 shares at $0.55, pending shareholder approval.
MBRXThe August filing assumed $2.22 per ADS. The September 4 pricing set a combined $1.00 with short-term warrants, for about $6 million of gross proceeds before fees.
PPBTJourney Medical signed an at-the-market sales agreement with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC for up to 3,750,000 shares. It ended an older B. Riley program under which it had sold 4,121,318 shares.
DERMCuranex closed its initial public offering of 3,750,000 shares at $4.00 a share on August 27, 2025. Dominari Securities led the underwriters, and the proceeds are earmarked for Phyto-N, a lead drug candidate for ulcerative colitis.
CURXThe FDA accepted the GTx-104 application on August 22, 2025, with an April 23, 2026 target date. Warrants from the September 2023 private placement, at $3.003 each, expire on the earlier of the 60th day after acceptance or September 25, 2028.
GRCEPiper Sandler & Co. and Cantor Fitzgerald & Co. are the agents under an August 25, 2025 equity distribution agreement. The company's latest annual report shows cash used in operations of CAD 1.9 million for fiscal 2024.
DRUGShattuck says the placement could fund operations into 2029 if all warrants are exercised. Two new directors join the board, including OrbiMed's Mona Ashiya, and four directors leave.
STTKIRONIovance may sell up to $350.0 million of stock through Jefferies, which can take up to 3.0% of gross proceeds. The company is not obliged to sell any shares, and its stock last traded at $2.60 on August 19, 2025.
IOVAAbout $15.7 million of stock remains available for sale after earlier sales of $4.3 million. The sales agent earns a 3.0% commission.
PLXSarepta would swap about $700.0 million of 1.25% notes due 2027 for $602.0 million of new 4.875% notes due 2030, about $123.3 million in cash and new shares. It also agreed to a $20.0 million private placement, with J. Wood Capital Advisors LLC as financial advisor and subscriber.
SRPTInvivyd sold 74,811,404 shares at $0.52 each and pre-funded warrants for up to 21,342,442 more shares, for a total public offering price of $49,997,865.68 before underwriting discounts.
IVVDPro-forma cash of about $226.8 million assumes the August offering, which added 76,666,659 ordinary shares. Reported cash and short-term investments were lower at June 30 than at the end of 2024, and the lead drug's efficacy data come from 10 of 12 patients.
NBPPharmaCyte agreed to sell 7,000 shares of Series C convertible preferred stock, with a $1,000 stated value each, to existing investors for $7.0 million. The preferred converts at $1.00 a share, against $4.00 for the 2023 Series B, and it carries a 7.0% quarterly dividend payable in cash.
PMCBPropanc sold 1,000,000 shares at $4.00 each, while its prospectus carries a going-concern warning and reports $50,760 of cash on March 31, 2025. The stock left the OTC Pink market for the Nasdaq Capital Market.
PPCBThe offering combines common stock units and pre-funded warrant units, each with a Series I warrant exercisable at $2.00 for five years.
CLDIAquestive sold 21,250,000 shares at $4.00 through Leerink Partners, Cantor and Oppenheimer, a day after agreeing to a conditional $75 million revenue-interest deal with an affiliate of RTW Investments. Anaphylm's approval is a condition of that deal.
AQSTVivani's Share Purchase Agreement with an entity affiliated with a director and another investor is expected to close in stages through July 15, 2026. The company says the proceeds secure its financial position into the second half of 2026.
VANIThe Open Market Sale Agreement with Jefferies is dated June 23, 2023. Enliven's common stock is listed on the Nasdaq Global Select Market.
ELVNProMIS filed a $50,000,000 base shelf on Form S-3 and an at-the-market agreement with H.C. Wainwright & Co. for up to $17,988,524 of common shares, at a commission of up to 3.0%. The stock closed at $0.628 on August 11, 2025, and the supplement does not explain its float figures.
PMNVivani sells 7,936,507 shares at $1.26 to two buyers, one of them tied to chairman Gregg Williams. Cash was $8.1 million at June 30, 2025, and the release presents the new money as securing its position into the second half of 2026.
VANICompass is selling 33,290,000 shares and pre-funded warrants for 6,710,000 shares. Proceeds before expenses are $112,800,000.
CMPXDiaMedica agreed to sell up to $100.0 million of common shares through TD Securities (USA) LLC, which can earn up to 3.0% of gross proceeds. No sale can be made until the Form S-3 is declared effective, and the filings give no cash balance.
DMACStifel is sole placement agent for the PIPE, which Coastlands Capital led at $1.42 per share. Closing was expected on or about August 13, 2025.
XFORThinkEquity was sole underwriter for 5,620,000 units and 380,000 pre-funded units. Warrants carry a $2.50 exercise price and trade as BIVIW; BioVie plans to use the money for working capital.
BIVIThe registered direct offering covers 20,000,000 shares and warrants for 20,000,000 more at $1.50. Full warrant exercise could bring up to $30 million more.
OCGNNet proceeds were about $15.2 million after fees and expenses. The company plans to start a Phase IIa concussion trial in Q3 2025.
OGENBioVie priced 6,000,000 units, including pre-funded units, at $2.00 each for about $12 million. ThinkEquity is sole book-running manager, and the prospectus says the financial statements raise substantial doubt about the company's ability to continue as a going concern.
BIVIProcessa says the private placement closed August 6, 2025, with LifeSci Capital LLC as exclusive placement agent. The company also says it is evaluating corporate cryptocurrency treasury strategies.
PCSAHelix says about $120 million remains in trust after redemptions, and that a $261 million private placement led by Cormorant Asset Management would bring the merger with BBOT to about $382 million gross.
BBOTCosmos Health agreed to issue up to $300 million of senior secured convertible promissory notes, with at least 72.5% of each tranche's net proceeds going to an Ethereum reserve. Curvature Securities, LLC was the sole placement agent, and the release gives no note terms or investor name.
COSMSana sold 20,895,522 shares at $3.35 plus pre-funded warrants for 1,492,537 more, with about $70.0 million in estimated net proceeds. It reported about $90.1 million in cash at July 31, 2025 and estimates $40.0 million to $45.0 million in facility impairments.
SANAHolders got one non-voting preferred share for every four common shares. The shares convert one-for-one only after FDA approval of an AVERSA-based product.
NTRBIntensity sold 19,868,658 shares at an average of $0.3323 each under its at-the-market program in July 2025. The company says its cash now reaches into the second half of 2026, but the release gives no cash balance.
INTSAlzamend Neuro (Nasdaq: ALZN) issued 243,429 common shares between July 23 and July 30, 2025 on conversion of Series B Convertible Preferred Stock. It had 3,139,861 common shares outstanding on July 30.
ALZNAIM ImmunoTech sold units at $4.00 with two warrants each, a month after a 1-for-100 reverse split, and its prospectus says there is likely substantial doubt about its ability to continue as a going concern. It must lift stockholders' equity to at least $6 million by June 11, 2026.
AIMGross proceeds would be $5,749,400. The price compares with a last reported sale of $1.1750 on July 29, 2025. An executive agreed to buy 26,000 shares.
DYAIPrime sold 38,000,000 shares at $3.30, below the $3.83 closing price on July 29, 2025. The estimated net proceeds are $120.2 million, and the auditor's 2024 report carries a going-concern paragraph.
PRMECingulate reported on July 25, 2025 that it issued common stock in three transactions with a lender, in exchange for part of the debt it owes, at $4.18 to $4.79 a share. The filing also covers a 7,538-share issuance to a service provider and a 30,000-share officer option grant. It names no bank or placement agent.
CINGA holder will exercise 4,318,905 Palisade warrants at a reduced price and receive new warrants for up to 8,637,810 shares. Ladenburg Thalmann is the placement agent.
PALIThe company may sell common stock from time to time but is not obligated to sell any. TD Cowen can earn up to 3.0% in commissions.
AVXLThe Israeli company may sell American depositary shares from time to time and is not obligated to sell any. LifeSci Capital will earn a 3.0% commission.
CMMBCytoDyn filed a Form S-3 shelf that would let it offer up to $100,000,000 of stock, warrants, subscription rights and units. The stock is quoted on the OTCQB, where it closed at $0.29 on July 24, 2025, and the shelf cannot be used until it takes effect.
CYDYLyell's private placement starts with about $50 million at $13.32 per share. A second $50 million at $25.61 per share depends on a milestone within 12 months.
LYELPolar Asset Management Partners is buying 5,365,853 shares at a premium of approximately 14% to the closing price on the agreement date. Closing was expected on or about July 28, 2025.
OMERProcessa filed a new prospectus supplement that lets it sell up to $5,239,073 of stock through its at-the-market program with A.G.P./Alliance Global Partners. Its shares closed at $0.2497 on July 22, 2025, down from $0.40 on June 11, 2025, the date its public float was measured.
PCSAIncannex had already sold about $63,469,250 of stock under the program. A week later it said it has no plans to use the full capacity in the near term.
IXHLScilex will pay a $1,500,000 option fee in two installments. If the buyback is completed and paid in full, the maturity of the Tranche A Note moves to March 31, 2026.
ORMPDiaMedica will sell 8,606,426 common shares at $3.50 each, for expected gross proceeds of $30.1 million before fees. The 8-K names no placement agent, and the company used $22,076 thousand in operations in 2024 while its equity fell to $40,718 thousand.
DMACSAB Biotherapeutics expects about $175 million in gross proceeds from Series B preferred stock, convertible into 100,000,000 common shares at $1.75. Warrants could bring in up to $284 million more, and the conversion rights wait on a stockholder vote.
SABSSAB will issue convertible preferred stock convertible at $1.75 per share, plus warrants that could bring up to $284 million more if exercised in full. It expects cash to last into the middle of 2028.
SABS60 Degrees Pharmaceuticals priced 2,631,578 shares at $1.90 with warrants. About $5 million comes in up front, and the short-term warrants could bring in about $5 million more only if fully exercised for cash.
SXTPGain agreed to sell 4,501,640 shares and warrants for 2,250,820 shares at $3.11 per set through Newbridge Securities. It expects net proceeds of approximately $6.3 million, with closing expected on or about July 17, 2025.
GANXWindtree agreed on July 16, 2025 to sell about 60,000 shares of Series E preferred stock with warrants, and to use the money to buy BNB. The deal cannot close until shareholders approve it, and it lapses if approval is not obtained within 120 days.
WINTJefferies earns up to 3.0% of gross proceeds on the new $200,000,000 program. The stock last sold at $4.54 on July 11, 2025, and the second dosing group in the Phase 2 REGEN-007 trial missed statistical significance.
PROKThe amendment raises the amount of American depositary shares the company may sell under a sales agreement with Leerink Partners. It has not sold any under the agreement so far.
NBPRani Therapeutics filed a resale prospectus on July 11, 2025 covering up to 13,160,172 Class A shares issuable on exercise of a Series D warrant. The company says it will receive no proceeds from the resale itself.
RANINasus Pharma seeks to list 1,000,000 shares on NYSE American at $10.00 to $12.00. Its prospectus says current cash will not fund planned operations, which raises substantial doubt about going concern, and its epinephrine Phase 2 study included 12 patients.
NSRXRecursion issued 1,457,952 shares to Rallybio for its half of an ENPP1 venture, with more stock and cash due on milestones. The company's share issuance is capped at 19.9% of outstanding common stock, and the 8-K names no underwriter or placement agent.
RXRXThe board approved the program on July 1, 2025. It runs through December 31, 2026 and will be funded from existing cash on hand, but the 8-K gives no cash balance to measure that against.
COLLThinkEquity LLC will earn a 3.0% commission on shares sold. Lantern's public float was $46,607,112 as of July 3, 2025, which limits sales to one-third of that float in any 12-month period while the float stays below $75 million.
LTRNTevogen can sell up to $50,000,000 of common stock through A.G.P./Alliance Global Partners, which is paid 3.0% of gross proceeds. The company's net tangible book value was negative $7.72 million at March 31, 2025, and buyers at the $1.25 reference price would face $1.07 a share of dilution.
TVGNThe net loss widened to $3.3 million as third-party sales fell. Cash rose to $47,272,851, mainly because of a $15,000,000 share issue and related-party borrowings.
UPCOragenics closed a registered offering of 660,000 Series H preferred shares and warrants on July 2, 2025, for about $16.5 million gross. The preferred converts at $2.50 a share, the conversion price has no floor, and Dawson James Securities took 7.00% of gross proceeds as placement agent.
OGENAbeona received gross proceeds of $155 million on June 27, 2025. The company says unaudited cash, cash equivalents, restricted cash and short-term investments were approximately $225 million as of June 30, 2025.
ABEOEach unit carried one share and two warrants exercisable at $0.65. Estimated net proceeds are $5,582,557.50, and the lead program is a COVID-19 vaccine whose key comparison trial is still ahead.
GOVXThe company will sell up to 11,000 Series C preferred shares to fund the purchase of U.S. rights to Ameluz from its former parent. Its royalty falls to 12% or 15% of U.S. sales, while the parent takes a 10% post-money stake.
BFRIA single institutional investor is buying 1,952,363 shares or pre-funded warrants plus options on the same number of shares. H.C. Wainwright is placement agent.
INMThe prospectus puts the immediate dilution to new buyers at $4.97 per share. Cash was $19,377 thousand at March 31, 2025, against an accumulated deficit of $172,843 thousand.
INMBThe warrant holders net exercised in full after Zymeworks removed a 19.99% ownership cap. Shares outstanding rose to 74,844,505.
ZYMEThe deal pairs each share with a $7.00 warrant and is expected to bring in approximately $4.7 million in gross proceeds. Bios 2024 Co-Invest, LP, a current stockholder, is among the purchasers, and the filing says Bios would be deemed to own about 49.9% of the company.
ACTUAchieve priced 15,000,000 shares, each sold with a five-year warrant at $3.00, for $45,000,000 in gross proceeds, below the $3.51 last reported sale price on June 26, 2025. The company's 2024 annual report carried a going-concern warning.
ACHVVor Bio agreed to pay RemeGen a $45 million upfront payment and $80 million in warrants for global rights to telitacicept, excluding Greater China. The only efficacy result cited is from a China Phase 3 study, and initial global results are expected in the first half of 2027.
VORCandel Therapeutics agreed on June 24, 2025 to sell 3,221,395 shares at $4.67 each in a registered direct offering. The prospectus names no placement agent or underwriter, and some buyers are directors and executive officers.
CADLAN2 Therapeutics swapped 2,500,000 and 300,000 common shares for pre-funded warrants held by Coastlands Capital Partners LP on June 17 and June 19, 2025, and the 8-K reports no cash to the company from either exchange.
ANTXTheriva Biologics filed to sell up to $2,534,352 of stock through A.G.P./Alliance Global Partners, under a cap set by its public float. Its auditor's report carries a going-concern paragraph, and the main survival result in its lead trial has a p-value of 0.0546.
TOVXJyong Biotech, a Taiwan-based drug developer, priced 2,666,667 shares at $7.50 with Joseph Stone Capital, LLC as sole underwriter. Its lead candidate failed its primary endpoint in a pivotal U.S. trial, its auditor has raised going-concern doubt, and a Chinese court judgment puts about USD 19.4 million at stake.
MENSInvestors in a March 2025 private placement agreed to cancel all Series A warrants and cut Series B warrant shares to up to 35,536,380. Lincoln Park may buy up to $50.0 million of stock over 36 months.
CNSYHolders of existing PolyPid warrants will exercise them for $26.7 million at $3.50 per share and receive new warrants at $4.50. The company ties the money to a Phase 3 trial whose effect size its release does not give.
PYPDNextCure agreed to pay Hainan Simcere Zaiming $17 million, including a $12 million upfront payment, for rights to a Phase 1 antibody drug conjugate. A Zaiming affiliate agreed to buy 4,063,633 shares for $2.0 million, and the company now says its cash lasts into mid-2026, not the second half of 2026 that its March 6 annual report gave.
NXTCAptevo filed to sell up to 1,709,401 shares with five common warrants each and signed a $25.0 million equity line with Yorkville. Its auditor's report carries a going concern paragraph, and cash was $2,139 thousand at March 31, 2025.
APVOAn 8-K filed June 13, 2025 reports the sale. Certain insiders had agreed in April to buy up to $10,000,000 of stock at $3.25 per share in the private placement.
RZLTQuince Therapeutics agreed to sell about $11.5 million of stock and warrants to institutional investors and three executives, and up to $10.4 million more depends on holders paying $1.20 per share.
IRLAQNCXThe sales were priced at about $3.03 per ADS, a 3% discount to market. Scinai also says a cost-cutting program will lower annual employment costs by about $815,000.
SCNITempest sold 405,000 shares and prefunded warrants for 334,000 shares to one institutional investor at $6.25 each, for about $4.1 million net. The company's cash estimate runs only into the second quarter of 2026, and it is exploring strategic alternatives.
TPSTOKYO Pharma Limited says it sold $3,999,911 under an earlier $4,000,000 supplement and will make no more sales under it. The new program is with B. Riley Securities.
OKYOTonix set up two ways to sell new stock on June 11, 2025: up to $150.0 million through A.G.P./Alliance Global Partners and up to $75.0 million to Lincoln Park Capital Fund. Its lead drug has an FDA decision date of August 15, 2025.
TNXPHolders of warrants for 8,301,322 shares agreed to exercise at a reduced price of $0.3041 per share. Ladenburg Thalmann & Co. Inc. is placement agent, and closing is expected on or about June 6, 2025.
CLRBAvalo ended an earlier $50.0 million sales agreement with Oppenheimer. Its stock last sold at $3.72 on May 29, 2025.
AVTXBon Natural Life's board approved a share repurchase of up to $1.0 million of its Class A ordinary shares, to be bought in the open market by TradeUp Securities as exclusive agent. The company says it is not obliged to buy any particular number of shares and may suspend the program at any time.
BONAdagene Inc. filed a prospectus supplement for an at-the-market program of up to US$100 million of American depositary shares, sold through Leerink Partners. The filing repeats the warning that its auditor is in mainland China, where trading in its ADSs could be barred.
ADAGMaxim Group LLC is the exclusive sales agent for up to $9,700,000 of stock, for a 3.0% commission. Two days earlier, Nasdaq had determined to delist ReShape, whose stockholders' equity was $1.2 million at March 31, 2025.
HINDB. Riley Securities and Alliance Global Partners will act as sales agents for a 3% commission. The stock's last reported sale price was $1.10 on May 27, 2025.
RVPHORIC Pharmaceuticals agreed to sell about 19.2 million shares or pre-funded warrants at $6.50 in a private placement with roughly $125 million in gross proceeds. The company says the cash funds operations into the second half of 2027, a runway tied to a Phase 3 readout it has not yet reported.
ORICMAIA Biotechnology (NYSE American: MAIA) expects gross proceeds of approximately $695,000 from shares sold at $1.50 with warrants at $1.71. A director is among the buyers, and closing is expected May 29, 2025.
MAIAImmunic began an underwritten warrant offering on May 28, 2025 and set final terms on May 30: $0.7499 a unit, $64,991,334 in total. Leerink Partners is sole bookrunner.
IMUXLexeo Therapeutics agreed to a private placement of 20,790,120 shares and pre-funded warrants for 6,963,556 more, with common warrants attached, for gross proceeds the company expects to be about $80 million. Part of that figure depends on warrants that have not been exercised, and the runway it cites depends on a 2027 readout.
LXEOA new purchaser joined the Series L 10% Convertible Preferred deal, which now carries an aggregate purchase price of $5,950,000.00. Buyers also hold greenshoe rights for up to $21,616,514 more.
GTBPLexeo expects gross proceeds of approximately $80 million from 20,790,120 shares or pre-funded warrants at $2.8825, with common warrants struck at $2.82.
LXEOTelomir sold 1 million restricted shares at $3.00 each to The Bayshore Trust, an entity affiliated with its largest shareholder. The price is 18% above the $2.54 closing price on the day of signing, and an earlier insider purchase in December 2024 was made at $7.00 a share.
TELORani Therapeutics cut the exercise price of two outstanding warrants from $3.08 and $3.00 to $0.65 so an existing institutional investor would exercise them, for gross proceeds of about $4.3 million before advisory fees. The investor also receives a new Series D warrant for up to 13,160,172 shares.
RANIChina SXT sold 10,000,000 shares with two warrants each for a combined $0.51 a share. The warrant exercise price resets to $0.24 on the seventh day, and the warrants could cover up to 100,000,000 shares. No placement agent or underwriter was used.
SXTCThe deal includes 834,237 shares and pre-funded warrants for 1,587,108 more. Atara plans to use the money toward approval of tab-cel.
ATRAEach unit carries two warrants exercisable at $7.45, and Maxim Group was sole placement agent. The prospectus carries going-concern doubt and a Nasdaq compliance warning.
HCWBMetaVia sold 9,479,345 shares at $0.71 each and pre-funded warrants for 4,605,162 shares. Ladenburg Thalmann was the exclusive placement agent, for a cash fee of 9.0% of gross proceeds.
MTVAInvestors are buying 9,479,345 shares at $0.71 and 4,605,162 pre-funded warrants. Proceeds go mainly to development of obesity candidate DA-1726.
MTVAOncolytics had cash of 15,303 thousand Canadian dollars at March 31, 2025, and said it can fund operations through the third quarter of 2025.
ONCYAbeona received the voucher when the FDA approved ZEVASKYN on April 28, 2025. The company says the proceeds give it cash for more than two years of operating expenses, but the release does not name the buyer.
ABEOLeerink Partners earns 3.0% of any gross proceeds, and CervoMed is not obliged to sell any shares. The prospectus supplement notes an auditor going-concern paragraph.
CRVOThe new shelf replaces one that expires on September 12, 2025. Jefferies LLC would earn up to 3.0% on ATM sales, and Tango's stock closed at $1.10 per share on May 8, 2025.
TNGXThe company also granted fully vested options at $2.86 per share to its interim chief executive and directors.
ZEOXApimeds is selling 3,375,000 shares at $4.00 for $13.5 million gross and listing on the NYSE American as APUS. Its controlling holder stays above 54%, and the company carries a going-concern paragraph from its auditor.
APUSNuvectis can sell up to $60 million of stock through Leerink. It ended an earlier $40 million program with H.C. Wainwright after selling about $18.6 million under it.
NVCTElutia receives no cash from the issuance. In its first-quarter results it said the change reduces cash outflows by $2.2 million in H1 2025.
ELUTJefferies LLC is the sales agent under an Open Market Sale Agreement for the $100,000,000 at-the-market portion. The May 7, 2025 filing gives a last reported sale price of $4.36 on May 5, 2025 and does not state a cash balance.
DSGNThe agreement covers up to $20,000,000 of stock, but small-float limits cap current sales at $2,994,080.
KRSAThe combined price of $0.6454 per ADS is set below the $1.10 last sale price on May 5, 2025. Warrant terms and a zero exercise price option on the Series B warrants could issue far more ADSs than the 2,452,935 sold.
NCNAThe amount is what remains under a $75,000,000 sales agreement with Guggenheim Securities after $25,000,000 was sold earlier. Dilution to new buyers at the May 2 price is $4.05 per share, and the company has recorded net losses in every year since it was founded.
COGTThe bonds of KC Creation Co., Ltd. mature on April 30, 2028 and yield 2.9% a year. KC Creation expects to use the money to buy stocks of other corporations.
XCURThe May 1, 2025 registration statement covered up to 3,246,753 shares at an assumed $1.54. The deal priced on May 6, 2025 at $1.40 for 3,571,428 shares or pre-funded warrants.
KTTAHolders agreed to exercise Series A and Series B warrants for cash at $0.1784 to $0.1844 per share by May 2, 2025. Two holders will swap warrants for pre-funded warrants, and IN8bio will cut the price of certain other Series B warrants to $0.45.
INABSerina can sell up to $13,270,500 of stock through JonesTrading, which earns up to a 3.0% commission. Its auditor has raised going concern doubt, its lead drug is still preclinical, and the program's size is capped by an SEC float rule.
SERVerastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.
VSTMThe investor is a company wholly beneficially owned by director Alejandro Weinstein. The new warrants can be exercised only after shareholder approvals required by Nasdaq rules.
PLURVerastem is raising about $75 million, with RTW Investments leading, ahead of a June 30, 2025 FDA action date. About $51 million of it is pre-funded warrants rather than common stock.
VSTMThe offering is a best-efforts deal placed by Laidlaw & Company (UK) Ltd. Warrant terms with a zero exercise price option and reset provisions could push the number of ADSs issued far above the 16,049,383 offered.
NCNARezolute will sell 20,786,923 shares at $3.25 and pre-funded warrants for up to 6,905,385 shares, through Guggenheim Securities as representative of the underwriters. Estimated net proceeds are $84.2 million, and insiders separately agreed to buy up to $10,000,000 of stock at the same price.
RZLTAbout $5 million is expected at the first closing. The company said the money will also help address Nasdaq shareholders' equity deficiencies.
CEROPacira BioSciences says its board approved a $300.0 million repurchase program on April 17, 2025, replacing the program announced in May 2024, while EXPAREL still accounts for most of its revenue.
PCRXCitius Pharmaceuticals sold one share of a newly designated Series A preferred stock for $100 to Chairman and CEO Leonard Mazur on April 17, 2025. The share carries 1,000,000,000 votes on a proposal to raise authorized common shares from 16,000,000 to 250,000,000, and the board also cut the quorum for stockholder meetings to one-third.
CTXRShareholders will surrender 3.5 million and 3.0 million Class A ordinary shares for no consideration and receive pre-funded warrants with a $0.001 exercise price.
ZURACadrenal can sell up to $2,169,272 of common stock through H.C. Wainwright & Co., LLC, after it has already sold $7,655,240 under the same agreement. The sales are capped by an SEC rule that applies because its public float is under $75 million.
CVKDImmunic agreed on April 9, 2025 to sell 5,666,667 shares at $0.90 each for about $5.1 million, with Titan Partners Group LLC as sole placement agent. The company's 2024 annual report carried a going concern doubt and reported $35.7 million in cash at year end.
IMUXTraws Pharma raised its at-the-market limit to $7,427,749 under the baby shelf cap, after selling 42,100 shares for about $122,210. The float that sets the cap uses an $8.29 high close, while the stock closed at $1.96 on April 4, 2025.
TRAWBoundless Bio filed a Form S-3 on April 1, 2025 covering up to $400.0 million of securities. The same day it signed an at-the-market sales agreement with Jefferies LLC for up to $14.5 million of common stock, which can start only after the SEC declares the registration effective.
BOLDThe buyback depends on closing the sale of the UDENYCA franchise. Coherus plans to buy back the remaining $60 million after that deal closes.
CHRSThe board approved the Share Repurchase Program on March 31, 2025. The 8-K says the full terms are in a press release attached as Exhibit 99.1, and the 8-K body gives none of them.
EBSInstil Bio signed a $100 million at-the-market sales agreement with Jefferies, which earns 3.0 percent of gross sales. The last reported sale price before the filing was $19.36, and the lead drug's clinical data come from a partner's small Chinese trial.
TILSurrozen sold 6,586,415 units in a first closing on March 26, 2025, for about $76.4 million gross before fees. Placement agent Guggenheim Securities, LLC was named in the purchase agreement. A second closing of about $98.6 million depends on FDA clearance of the SZN-8141 IND by October 31, 2026.
SRZNDermata agreed with holders of warrants for 4,834,470 shares to exercise at a reduced $1.284 a share, for about $6.2 million before fees. In return they receive new Series A and Series B warrants for up to 4,980,806 and 4,688,134 shares.
DRMAThe shares come from Series B and Series C preferred stock and placement agent warrants tied to its private offerings. On April 4, 2025 Lipella added an at-the-market program of up to $2,641,881.
LIPORelmada Therapeutics agreed on March 24, 2025 to license NDV-01 from Trigone Pharma for a $3,500,000 upfront fee and 3,017,420 restricted shares, which the press release says is 10% of its outstanding stock. Milestones can reach $200 million, and from 2026 Relmada must spend at least $5,000,000 a year on the drug.
RLMDBenitec Biopharma is issuing 2,043,000 shares and 300,000 pre-funded warrants at $13.00 a share. The prospectus says 900,000 of the shares go directly to Averill funds that are affiliates of Suvretta Capital, while the pricing release names Suvretta Capital itself.
BNTCPrecision BioSciences, Inc. became subject to a one-third-of-float cap on shelf offerings on March 26, 2025, when it filed its 2024 annual report. It filed a supplement to its Jefferies at-the-market program to reflect that.
DTILThe smaller size reflects an SEC limit tied to MAIA's public float. The company has sold about $11,633,086 of stock under the agreement so far.
MAIAThe sales agent earns up to 3.0% of gross sales. Climb Bio reported $212.5 million of cash and securities at year end and expects to fund operations through 2027.
CLYMNet proceeds are about $9.1 million. The auditor has raised going-concern doubt, and preliminary year-end cash was $30.9 million.
GNLXThe prospectus puts gross proceeds at $4,999,878 and says auditors have raised going-concern doubt. Cash covers operations into the third quarter of 2025 with the money.
GRINeOnc's prospectus registers 2,101,313 shares for resale in a Nasdaq direct listing, and the company gets none of the proceeds. Its financial advisor RBW Capital Partners is also the placement agent for a $10 million private placement, and the auditor's report carries a going concern paragraph.
NTHITransCode is selling 10,250,000 shares and warrants at $0.98 per share and warrant, through ThinkEquity LLC as exclusive placement agent, for a total offering price of $10,045,000 before fees. The prospectus shows an immediate dilution of $0.72 per share to new investors, and the auditor's report carries a going concern paragraph.
RNAZThe Nasdaq-listed company sold shares, warrants and pre-funded warrants through Craig-Hallum for gross proceeds of approximately $20.0 million. Its CEO and board chairman bought in a separate private placement.
IRDLeerink Partners will act as sales agent for a 3.0% commission. The company's public float was approximately $57.81 million.
SNTIVaxart agreed on March 21, 2025 to sell up to $50 million of common stock through Citizens JMP Securities and B. Riley Securities, which may each receive a commission of up to 3% of gross sales. The stock closed at $0.5754 on March 17, 2025.
VXRTThe company has sold 2,522,755 shares for about $23.75 million so far under the program. It had 2,944,381 shares outstanding as of March 20, 2025.
CNSPAn amendment with TD Cowen cuts the program to $100 million, and the 8-K gives no reason for the cut. The new supplement shows immediate dilution of $3.78 per share at the $4.44 reference price.
FHTXAkebia priced 25,000,000 shares at $2.00 for gross proceeds of $50.0 million, below the $2.84 last sale price the final prospectus cites for March 19, 2025. The company estimates net proceeds of about $46.5 million and reports an accumulated deficit of $1,678,360 thousand.
AKBAMilestone amended its Jefferies sales agreement to allow up to $75,000,000 of new common shares, within a $77,800,000 total that includes about $2.8 million already sold. Jefferies can earn up to 3.0% commission, and the shares closed at $2.41 on March 17, 2025.
MISTOPKO bought 3,685,226 Entera ordinary shares at about $2.17. Entera will hold the money in escrow to fund its 40% share of development costs. Entera can opt out after Phase 1.
ENTXThe two companies will hold 60% and 40% ownership interests in an oral GLP-1/glucagon program. Entera says the proceeds will fund its 40% share through Phase 1.
ENTXOPKMetagenomi filed a $250,000,000 shelf and signed a $75,000,000 at-the-market sales agreement with Jefferies LLC, which can earn up to 3.0% commission. The filing does not state the company's cash balance, and sales can start only after the registration statement is declared effective.
MGXRallybio cut its at-the-market stock program from $100,000,000 to $9,550,000 on March 13, 2025. The company says it has sold no shares under the agreement, and the cut follows an SEC rule that limits sales for companies with a public float below $75.0 million.
RLYBEterna Therapeutics (now Ernexa Therapeutics, Nasdaq: ERNA) received $1,500,000 on March 11, 2025, under a promissory note with 5.0% interest that matures no later than June 15, 2025.
ERNADogwood will cancel its loans from Conjoint Inc., a subsidiary of its largest shareholder, for 284.2638 shares of Series A-1 preferred stock convertible into 10,000 common shares each.
DWTXViking Therapeutics' Irish subsidiary agreed on March 10, 2025 to make prepayments to CordenPharma for supply of its obesity candidate VK2735. The 8-K puts the prepayments at $90.0 million through 2028, and the press release gives a $150 million total. This is money Viking pays out, not money it raises, and neither document gives a cash balance against which to test it.
VKTXLeerink Partners will earn 3.0% of gross proceeds on any sales. The stock last sold at $0.8449 on March 10, 2025.
XLOAcurx Pharmaceuticals sold 2,150,000 shares and pre-funded warrants for 595,000 more at about $0.40 each, and added private warrants for up to 8,235,000 shares. The price is far below the $1.015 the company got in a January offering, and a Nasdaq bid-price notice arrived on February 24, 2025.
ACXPHolders of warrants for 837,104 shares agreed to exercise at $4.42 per share and receive new warrants at $3.75. Roth Capital Partners acted as financial advisor.
CELZThe company will not receive any proceeds from sales by the stockholder. The shares were acquired under a stock purchase agreement dated November 25, 2024.
ARWRReplimune's board grew from nine to ten members on March 5, 2025 to seat Michael Goller, an employee of Baker Bros. Advisors. The same day the company agreed to resale registration rights for the BBA Funds, which bought stock in two financings in 2024.
REPLNuvation Bio's automatic shelf lets it sell up to $200,000,000 of common stock through Jefferies LLC as sales agent, at up to 3.0% of gross proceeds. The stock last sold at $1.82 on March 4, 2025, and the company's lead drug is still waiting on an FDA decision.
NUVBRTW is to buy 378,346 shares at $6.04 and pre-funded warrants for 3,760,726 shares. Tenax plans to use the money for Phase 3 trials.
TENXAadi Bioscience closed a private placement of about $100 million on March 4, 2025, selling 21,592,000 shares at $2.40 and pre-funded warrants for 20,076,500 more shares. The company says the money, with the FYARRO sale, should fund operations into 2028.
WHWKTenaya priced 75,000,000 units at $0.70 for about $52.5 million, with two warrant series attached to each unit. Its lead gene therapies are in early trials with only a few patients dosed, and the stock's last reported sale price on the pricing day was $0.9469.
TNYAAbCellera's common shares last sold at $2.92 per share on February 26, 2025. The prospectus sets no dollar amount for the offerings and names no bank or agent.
ABCLAltimmune's $400 million shelf would also carry a $150 million share sales program, with Leerink Partners, Piper Sandler and Stifel as sales agents. The filing itself sells no shares.
ALTShuttle paid Alto Opportunity Master Fund $75,000 under an amendment signed February 26, 2025. The holder gave up its right to buy up to $10 million of additional notes and warrants, and waived its right to join a contemplated registered offering.
SHPHThe company expects the sale to close within 30 to 45 days, subject to customary conditions including a Hart-Scott-Rodino waiting period.
ZVRASINTX (Nasdaq: SINT) sold shares, pre-funded warrants and warrants for gross proceeds of $5.0 million before fees. H.C. Wainwright & Co. was placement agent, and the company will use net proceeds for working capital.
SINTThe interest rate on the notes rises from 8% to 9%, and Agenus will grant a subordinate mortgage on properties owned by Agenus West, LLC. New warrants cover 67,500 shares.
AGENMAIA Biotechnology agreed on February 24, 2025 to sell 894,300 shares at $1.50 each, with warrants at $1.85, to accredited investors and certain directors. Combined gross proceeds are expected to be about $1.43 million, and the company's 2023 annual report carried a going-concern warning.
MAIAInhibikase paid $15.0 million for CorHepta in 4,979,101 newly issued shares, with part held in escrow or tied to a milestone. The 8-K names no bank, placement agent or financial adviser for the stock issuance.
IKTBofA Securities will sell shares as agent for a commission of up to 3.0%. The stock last sold at $0.7724 before the filing.
KYNBUroGen paid for IconOVir Bio's ICVB-1042 candidate with shares tied to a $4.0 million price, a possible $15.0 million sales milestone and a low single-digit royalty. Entities tied to UroGen's board chair hold IconOVir notes.
URGNThe deal covers the product candidate ICVB-1042. A director's affiliates hold IconOVir notes that may entitle them to about 28.3% of the purchase price.
URGNThe Second Tranche loan matures on April 30, 2029. Warrants issued to the initial lender and its affiliate carry an exercise price of $5.4787 and a term of 7 years.
TLSIThe notes mature in 2028, 2030, 2035 and 2055. AbbVie plans to use the money and cash on hand to repay 2025 senior notes, and the sale is expected to close February 26, 2025.
ABBVPetros is selling about 40,000,000 shares, or pre-funded warrants in their place, at $0.24 for about $9.6 million gross. Dawson James Securities, Inc. is the placement agent, paid 8% of the gross proceeds, and the warrants cannot be exercised until stockholders approve them.
PTPIThe sales agreement with H.C. Wainwright still limits what it can sell now to $5,800,000, because of a cap tied to its public float.
CPIXEdesa sold 834 Series B-1 preferred shares at $10,000 each and 3,468,746 common shares at $1.92. A Velan Capital analyst joined its board.
EDSAAligos is selling shares, pre-funded warrants and warrants at $26.0825 per share and warrant to fund a Phase 2 study of ALG-000184 and extend cash into the second half of 2026.
ALGSMicrobot Medical agreed to sell 6,103,289 shares at $2.13 in a registered direct offering, with unregistered warrants for up to 12,206,578 more shares. H.C. Wainwright & Co., LLC is the exclusive placement agent, and the company pays it a 7.0% cash fee.
MBOTGrace Therapeutics expects about $13.8 million in net proceeds from a private placement at $3.395 a share, with TD Securities (USA) LLC as placement agent. The same day, its Phase 3 safety trial of GTx-104 was reported, and the company's own release says the trial was not powered to show efficacy.
GRCEBelite Bio is selling 258,309 ADSs and warrants for the same number of ADSs at $58.07 each through Titan Partners Group LLC. The prospectus says the company has recorded net cash outflows from operations since inception.
BLTEThe warrants can be exercised only after stockholders approve. The offering follows a 1-for-50 reverse stock split on January 15, 2025.
MBIOFBIOThe offering totals $190,588,194, and the stock is approved to list on Nasdaq under SION. Proceeds to the company are $177,247,020 before expenses.
SION60 Degrees Pharmaceuticals sold 1,503,500 shares at $0.715 each in a registered direct offering that closed Feb 6, 2025. H.C. Wainwright was the placement agent, and the company reports about $908,627 of net proceeds, with matching warrants at $0.59.
SXTPRenovoRx sold 11,523,810 shares at $1.05, below the $1.46 last sale on February 6, 2025, with Titan Partners Group as sole bookrunner. The company held about $9.6 million in cash and short-term securities at September 30, 2024, and its prospectus carries a going concern paragraph.
RNXTBriaCell sold 762,500 common shares at $4.00 each through placement agent ThinkEquity. The $3.05 million in gross proceeds is before fees and expenses, and the agent also received warrants on 38,125 shares.
BCTXAlto Neuroscience filed a $300,000,000 shelf on February 3, 2025 and signed a $75,000,000 at-the-market sales agreement with Leerink Partners LLC, but no sale can start until the SEC declares the shelf effective, and its year-end cash figure is still preliminary.
ANROAnnovis Bio priced 5,250,000 units at $4.00 for $21,000,000 on February 3, 2025, through ThinkEquity as underwriter, with a $1,260,000 discount and warrants exercisable at $5.00, which is 125% of the offering price.
ANVSJefferies is the sales agent. ArriVent's stock last sold at $29.09 per share on January 30, 2025.
AVBPH.C. Wainwright & Co. is the exclusive placement agent for a $3.00 offering of shares and warrants. The auditor's report on the 2023 financial statements already raised substantial doubt about the company's ability to continue as a going concern.
ENVBBeta Bionics told the SEC that its initial public offering and a concurrent private placement brought in gross proceeds of $229.1 million before underwriting discounts and expenses. The company's own release puts its share of the IPO at about $212.1 million, well below the $234.6 million headline figure.
BBNXMaze priced at $16.00 and expects net proceeds of approximately $127.7 million. The company reported a net loss of $100.4 million for 2023 and has no product approved for sale.
MAZETectonic's January 30, 2025 presentation put cash at $159 million as of September 30, 2024. On February 3 it agreed to a $185.0 million PIPE, with 3,689,465 shares sold at $50.00 each to funds and $54.14 each to officers and directors.
TECXLineage received $6 million more after shareholders approved a sale to a director's affiliate. Milestone-linked warrants could add up to $36 million.
LCTXThe ADSs are approved to list on Nasdaq under AAPG, with J.P. Morgan and Citigroup as the underwriters named on the cover. The company's ordinary shares have traded in Hong Kong under code 6855 since October 28, 2019.
6855The company applied to list on the Nasdaq Global Market. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are the underwriters named on the cover.
AARDPhio sold 610,000 shares at $3.00 per share and issued short-term warrants for up to 1,220,000 shares in a concurrent private placement. Net proceeds are approximately $1.6 million, after a placement agent fee of 7.5% plus a 1.0% management fee.
PHIOKairos Pharma (NYSE American: KAPA) sold 2,500,000 pre-funded units, each with a common warrant at $1.40 per share. Boustead Securities and D. Boral Capital were co-placement agents.
KAPASionna Therapeutics filed a preliminary S-1 on January 17, 2025 for an IPO of common stock on the Nasdaq Global Market under SION. The filing leaves the share count, price range and net proceeds blank, and lists Goldman Sachs & Co. LLC, TD Cowen, Stifel and Guggenheim Securities as underwriters without marking a lead.
SIONiBio sold 240,807 common shares at $2.72 each to its directors and officers, for about $655,000 in gross proceeds, and the placement closed on January 10, 2025. The company says the price was at-the-market.
IBIOOpus Genetics can sell up to $40,000,000 of stock through Leerink Partners, which takes 3.0% of gross proceeds. The company's last reported sale price was $1.42 on January 10, 2025, and the earlier JonesTrading program had sold about $26.4 million of stock.
IRDProtara's January 2025 presentation says cash runway reaches into 2027 when it counts $102.7 million of gross proceeds from a recent offering. Its balance sheet figure is $81.5 million at September 30, 2024, and its bladder cancer efficacy data come from a small single-arm trial.
TARAEach ADS sells for $4.275 with a warrant to buy another at $5.796. Full cash exercise of the warrants could lift gross proceeds to about $353 million.
CMPSEntera Bio Ltd. nearly used up the 5,000,000 shares first registered with Leerink Partners. The new supplement covers an additional block under the same sales agreement.
ENTXThe company also agreed to sell units to Deer Light Ltd. for $137,000 and has received about $120,000 so far.
SKTGAcurx will sell 2,463,058 shares at $1.015 to institutional investors and six insiders, with Series E warrants for the same number of shares at $0.90. H.C. Wainwright & Co. is the exclusive placement agent, and it receives a 7.0% cash fee plus a 1.0% management fee.
ACXPThe contract manufacturer received $7 million at closing and expects the rest in three tranches over 18 months. It says current capacity supports up to $300 million in annual revenue.
LFCRMaze's IPO filing names four underwriters and leaves the share count and price range blank. The nine months to September 30, 2024 include $167,500 thousand of license revenue.
MAZEIt is the third such letter agreement with Lind Global Fund II, LP. The company agreed not to issue new shares for 15 days after closing.
ABVCAEON Biopharma priced 40,000,000 units at $0.50 each for about $20.0 million gross, with Aegis Capital Corp. as sole book-running manager. Each unit carries two warrants that cannot be exercised until stockholders approve them, and their exercise price can reset lower.
AEONiBio agreed to license an anti-myostatin antibody from AstralBio and paid the $750,000 upfront fee in common stock. AstralBio can earn up to $28 million in milestones, and the antibody's data so far are preclinical.
IBIOThe company is selling 1,340,603 shares at $6.44 and 3,286 Series I preferred shares at $644.00. It expects the money to fund operations into the first quarter of 2026.
KALAPrecigen agreed to sell 8.00% Series A convertible perpetual preferred stock for anticipated gross proceeds of $79.0 million, with warrants for 52,666,669 shares at $0.75 attached. The company says the money extends its cash runway into 2026, provided the PRGN-2012 launch comes after approval.
PGENThe Cayman Islands company's shares have traded in Hong Kong under stock code 6855 since October 28, 2019. The ADS count and price are blank, and J.P. Morgan and Citigroup are named on the cover.
6855TScan sold pre-funded warrants for 7,500,000 voting shares at $4.00 each in a registered direct offering to Lynx1 entities, for about $30.0 million gross. It says cash will fund operations into the first quarter of 2027, on assumptions that may prove wrong.
TCRXThe shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024.
CNTXThe underwritten offering and a concurrent private placement are expected to bring net proceeds of about $37.6 million.
MNPRQuoin Pharmaceuticals priced a $6.8 million offering at $0.45 per ADS, below the $0.647 close on December 19. Older warrants were repriced to the same level, and the prospectus sets no minimum amount for the deal to close.
QNRXBioAtla is selling 9,679,158 shares with warrants at a combined $0.9520 each, through sole placement agent Tungsten Advisors, for about $9.2 million gross and about $8.5 million net.
BCABThe payment to Petrichor comes from available cash. It cuts about $1.5 million in annual interest and removes about 1.6 million potential shares.
FENCInvestors agreed to buy 1,783,805 shares plus warrants. The warrants need stockholder approval before they can be exercised.
MRKRSalarius Pharmaceuticals agreed on December 12, 2024 to let C/M Capital Master Fund, LP purchase up to $10 million of its common stock over 36 months, once a resale registration is effective. The 8-K names no placement agent or counsel, and it gives the company's Nasdaq symbol as SLRX.
DCOYTaysha Gene Therapies filed a $300,000,000 shelf registration on December 13, 2024, with a $100,000,000 at-the-market sales agreement inside it. The company had sold $12,000,000 under its earlier agreement, and the stock's last reported price was $2.25.
TSHAThe shares went to one institutional investor, and the prospectus says no placement agent or underwriter was involved. The prospectus puts the immediate dilution to the buyer at $11.35 per share.
ETONInovio is selling 10,000,000 shares at $3.00 with warrants for 10,000,000 more shares at $3.76. The filing gives net proceeds of about $27.6 million and immediate dilution of $0.19 per share.
INOThe company is selling 15,384,619 shares. The stock last traded at $2.44 on December 9, 2024. Cardiff plans to use proceeds for onvansertib trials in colorectal cancer.
CRDFRocket Pharmaceuticals priced 13,200,000 shares at $12.50 on December 10, 2024, below the $13.84 last sale price on December 9. Net proceeds are about $154.8 million before the underwriters' option, and the company's own prospectus says the money will last into the second quarter of 2026.
RCKTThe supplement covers up to $125,000,000 of common stock sold through Jefferies LLC under a February 4, 2022 sales agreement. Shares with an aggregate offering price of up to $22,182,550 remained unsold under the 2022 supplement, and the filing gives a $12.71 last sale price on December 4, 2024.
CELCJupiter Neurosciences priced a firm commitment IPO of 2,750,000 shares at $4.00, or $11,000,000 gross. Its prospectus carries a going concern warning and an accumulated deficit of $23,903,481 at June 30, 2024.
JUNSKorro Bio's S-3 shelf registers up to $400,000,000 of securities. Its sales agreement with TD Securities (USA) LLC covers up to $100,000,000 of common stock, and the filing gives no cash balance.
KRROOlema is selling 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares. Novartis will supply ribociclib for the planned Phase 3 OPERA-02 trial.
OLMAJefferies LLC is the sales agent for up to $50,000,000 of common stock. Its commission is up to 3.0% of gross proceeds, and a significant part of the business runs through a Chinese subsidiary.
GYREOramed and the Tranche B holders waived the missed quarterly filing on November 21, 2024. Scilex must deliver its September 2024 financial statements by January 20, 2025, through a new independent auditor.
SCLXB. Riley Securities is removed from the program. Raymond James and Roth Capital Partners will continue as the sales agents.
NAGEPMV can sell up to $113,792,846.40 of stock through Jefferies, which the filing says is paid 3.0% of gross proceeds. The stock last sold at $1.59 per share on November 19, 2024, far below the $6.97 weighted average on the earlier program.
PMVPVerrica priced 44,964,045 shares at $0.89 with Series A and B warrants, for a total public offering price of $42,007,776. Entities tied to director Paul B. Manning agreed to buy 22.9 million shares, and the filing carries a going-concern warning.
VRCAJefferies will earn a commission of up to 3.0% on any shares sold. The stock last sold at $1.28 on November 15, 2024.
ATOSAclaris also pointed to a private placement financing announced the same morning and said it maintains its cash runway into 2028. The release gives no license payment terms.
ACRSRockwell Medical may sell up to $25,000,000 of stock through Cantor Fitzgerald, which takes a commission of up to 3.0%. At the assumed $4.43 price, the filing says new buyers would face an immediate dilution of $3.33 a share.
RMTIThe balance includes net proceeds of a $50 million registered direct offering priced June 14, 2024. Third-quarter net loss was $15.0 million.
MREOJefferies will earn up to 3.0% of gross proceeds. The stock last sold at $16.65 before the agreement.
ASMBSCYNEXIS can sell up to $50,000,000 of stock through Cantor Fitzgerald, which earns a 3.0% commission, with the stock at $1.33 on November 5, 2024. Its approved drug is off the market under a recall, and the supplement gives no cash balance.
SCYXAnaptysBio's new shelf replaces one that expires January 11, 2025, and its $100,000,000 sales program with TD Securities (USA) LLC could sell up to 4,819,277 shares at $20.75 each, with immediate dilution of $15.59 per share for new buyers.
ANABNeurogene is selling 1,835,000 shares and pre-funded warrants for up to 2,165,042 shares to a group of healthcare investors.
NGNEStockholders approved the share issuances at the annual meeting on October 29, 2024, the same day the placement closed. The company also agreed to register the new shares for resale, and its equity had been below Nasdaq's $2.5 million minimum.
ERNAThe Swiss company plans to use the money for its radiopharmaceutical pipeline and working capital. Leerink Partners and TD Cowen are joint bookrunners.
MOLN
aibio